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ABSTRACT OF DISSERTATION

THE OFF-LABEL USE OF ATYPICAL ANTIPSYCHOTICS AND
ITS IMPACT ON ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Atypical antipsychotics (AAPs) (also known as second-generation antipsychotics)
are the US Food and Drug Administration (FDA) approved medications for
schizophrenia, bipolar I disorder, depression and autism. Compared to the typical
antipsychotics, AAPs were marketed as reducing adverse side effects such as
extrapyramidal symptoms. This resulted in extensive use of AAPs for not only the FDA
approved indications but also other conditions that are not approved. However, several
post-marketing clinical trials evaluated the use of AAPs and reported serious adverse
side effects, including metabolic syndrome, cardiovascular events, or death.
The extensive use of AAPs by pediatrics is an important policy problem that
imposes serious concerns on public health and economy in the US. A large proportion of
total pediatric AAP use is off-label in which the safety and effectiveness are not yet
established. Moreover, among the off-label conditions for which AAPs were used,
ADHD was the most common primary mental diagnosis.
From public health perspective, the risk of type II diabetes in pediatric AAP
users was estimated. A retrospective cohort study was conducted and a twice higher
risk of developing type II diabetes was estimated for AAP users compared to non-users
in pediatrics.
From economic efficiency perspective, the cost-effectiveness of AAPs compared
to other ADHD medications in pediatric ADHD patients was estimated. Among nonstimulant ADHD medication treatment strategies, AAPs resulted in the lower expected
health outcome than other ADHD medications. Also, AAPs were not a favored choice
with respect to cost-effectiveness. A comparative effectiveness study that compares
resource utilization and costs between atypical antipsychotic (AAP) users and non-AAP
users in ADHD revealed that AAP users were likely to visit a healthcare facility for
outpatient and inpatient services more frequently than non-AAP users. Total health care
costs were significantly higher for AAP users with additional costs of $1,393 (2012
dollars) during six months and $2,784 (2012 dollars) during a year after initiating the
AAP treatment.

KEYWORDS: Atypical antipsychotics (AAPs), Attention-deficit/hyperactivity disorder
(ADHD), Type II diabetes (T2DM), Cost-effectiveness, Comparative effectiveness
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Chapter 1: A review of ADHD and concerns related with atypical antipsychotics
(AAPs) use

A. Introduction
During the current transition to national healthcare reform, much more attention
is being paid to how the health care system is implemented than ever before. While it is
well known that health care reform will affect the number of individuals covered by
insurance, less is known about the clinical and economic impacts of the Patient
Protection and Affordable Care Act (PPACA). The PPACA addresses these with titles of:
1) “Improving the quality and efficiency of health care,” and 2) “Prevention of chronic
disease and improving public health. “ As described in the book Tracking Medicine,
written by John Wennberg, the U.S. health care delivery system shows unwarranted
variation that cannot be explained based on prevalence of illness, medical evidence, or
patient preference.1 Wennberg argues that undisciplined growth in health care and
spending has contributed to the overuse of health care resources.
Antipsychotic medications have long been used for treatment of mental
disorders including psychosis, schizophrenia and bipolar disorder. These medications
can be broadly categorized into two classes: (1) conventional antipsychotics, also known
as first generation antipsychotics or typical antipsychotics, which were discovered in
1950s.2 (2) Atypical antipsychotics (AAPs) (also known as second-generation
antipsychotics) were introduced during 1990s. Compared to the conventional
antipsychotics, AAPs were marketed as reducing adverse side effects such as
1

extrapyramidal symptoms. This resulted in extensive use of AAPs for not only the U.S.
Food and Drug Administration (FDA) approved indications but also other conditions
that are not approved. However, several post-marketing clinical trials evaluated the use
of AAPs and reported serious adverse side effects, including metabolic syndrome,
cardiovascular events, or death.3-5 Also, controversy exists over whether the unapproved
use of AAPs is justified in terms of effectiveness and safety.6-9 Nevertheless, AAPs are
one of the top-selling classes of pharmaceuticals in the US. In fact, antipsychotic
medications generated about $18.2 billion total revenue in 2011, with three individual
AAP agents accounting for 65% of the total revenue.10
This chapter is intended to review current issues related with unapproved use of
AAPs, specifically focusing on thier use in attention-deficit/hyperactivity disorder
(ADHD) children and adolescents. I start by providing general information about
ADHD such as symptoms, diagnostic process and prevalence, followed by ADHD
treatment options and costs of illness. Then, I motivate the study rationale for why AAP
use in ADHD is important from a public health perspective, as well as a social efficiency
perspective. Next, we give a systematic review of AAP use in the young population and
the associated clinical side effects. Lastly, with commentary about the systematic review,
future areas of research will be suggested.

B. ADHD symptoms, diagnosis, and prevalence
Attention-deficit/hyperactivity

disorder

(ADHD)

is

the

most

common

neurobehavioral disorder of childhood, characterized by having trouble paying
2

attention, not being able to control impulsive behaviors, or being overly active.11 Those
with ADHD may experience academic underachievement, troublesome interpersonal
relationship development, and low self-esteem. Core ADHD symptoms can be divided
by two dimensions based on psychometric properties. One is the inattention dimension
that includes symptoms such as making careless mistakes, having difficulty sustaining
attention, or being easily distracted. The other is hyperactivity-impulsivity dimension
that is characterized by symptoms such as being unable to stay seated, having difficulty
engaging in leisure activities quietly, or interrupting/intruding on others. ADHD
diagnosis is made when at least six or more core symptoms are present in either or both
of dimensions. Core symptoms of ADHD adapted from the DSM-IV-TR are shown in
Table 1. 1.
The prevalence of ADHD has been increased from 7.8% to 9.5 % during 20032007, according to the Center for Disease Control (CDC) in 2010.12 The increase in
prevalence can occur when the incidence increases. Some of the increase is due to the
way of patients are diagnosed or detected. Also, it is likely that the observed increase in
prevalence is explained by, in part, by the increased recognition of the condition. In fact,
the CDC report shows that twelve states had significant increases in the number of
diagnosed ADHD cases and this suggests that state policy or practice changes, such as
widespread behavioral health screening, could have resulted in the increased prevalence
rate. Furthermore, the diagnostic and treatment scope for ADHD has expanded as recent
clinical practice guidelines for ADHD, published by the American Academy of
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Pediatrics, expanded the age range of the recommendations from 6-12 years of age to 418 years of age.11

C. Treatment options for ADHD
Treatment options for ADHD include medication therapy and behavior therapy.
According to the ADHD clinical practice guideline, only behavioral therapy is
recommended for preschool-aged children (4-5 years of age) as the first line treatment.
For school-aged children and adolescents (6-18 years of age), the combination of
medication and behavioral therapies is preferred. Medication therapy usually initiates
with stimulants such as amphetamine derivatives (e.g., Adderall), which are FDAapproved medications for ADHD. Selective norepinephrine reuptake inhibitor
(atomoxetine) and selective α2-adrenergic agonists (clonidine, guanfacine) are also FDAapproved medications for ADHD management and are often considered as alternatives
or adjunctive therapy with stimulants. FDA-approved medications including their
generic and brand names are shown in Table 1. 2.
Typical behavioral therapy includes parent-training programs in which the
parents or caregivers of children with ADHD are educated with skills to manage
behavioral symptoms of their child. As another strategy, changing the physical
environment, such as the classroom, is also considered and recommended because it
could reduce stimuli that trigger behavioral symptoms. Although it has been shown
effective for ADHD management, behavioral therapy requires a high level of family
involvement and it might not be easily accessible for some patients.
4

D. Cost of illness
The ADHD patients experience substantial difficulties in many areas of their
lives, including academic underachievement, and impaired social functioning, which
may impact them the rest of their lives. For example, poorer social functioning among
ADHD patients was observed in several studies, which report that those with ADHD
have fewer close friends and are more frequently rejected by peers, compared to those
without ADHD.15-17 More importantly, according to the findings of Bagwell et al., these
problems are persistent from childhood to adolescence.15 They retrospectively followed
adolescents based on their ADHD history and found that impairments in peer relations
during adolescence were highly predicted by childhood ADHD.
ADHD also affects families and caregivers in a form of emotional distress or the
loss of work productivity, due to excessive care-giving effort required by ADHD
patients.14,18 Swensen et al., estimated medical care costs and costs associated with work
loss accrued to the family members of ADHD patients.14 They reported that ADHD
family members had a higher rate of mental disorders compared to their matched
controls. The prevalence of depression was more than twofold higher in the ADHD
family members (9% vs. 4%). They also showed that having an ADHD patient in the
family was associated with higher medical expenses for other family members, as well
as higher indirect costs generated from work absenteeism.

5

E. Atypical antipsychotics and ADHD
Economic burden of ADHD could vary significantly depending on the choice of
treatment regimen and how well the patient responds to the therapy. For example,
although the symptoms are successfully managed with stimulants in most ADHD
patients for the short term (6-10 weeks),19-21 an alternative medication regimen is often
considered due to the adverse side effects, tolerance development or lack of symptom
improvement. While atomoxetine, clonidine or guanfacine are recommended as the
alternative to stimulants, a growing number of ADHD children are prescribed with
AAPs.8,22,23 The AAP use is concerning because they are not approved for ADHD
management by FDA nor recommended by ADHD practice guidelines.
Atypical antipsychotics (AAPs, or second-generation antipsychotics) are a
relatively new class of antipsychotic medications. Frequently used AAPs are: olanzapine,
risperidone,

quetiapine,

ziprasidone,

paliperidone,

and

aripiprazole.

Atypical

antipsychotics are thought to block dopamine receptors as their mechanism of action,
except aripiprazole. Aripiprazole does not block the dopamine receptor but acts as a
partial agonist and reduces the receptor activation by competing with dopamine or
other full agonists. Atypical antipsychotics are FDA-approved for the treatment of
schizophrenia and bipolar mania, and a few have also been approved for autism
spectrum disorders and major depression. FDA-approved indications for AAPs and
their generic/brand names are shown in Table 1. 3.

6

The use of AAPs in children and adolescents with ADHD in practice is
potentially important from the public health standpoint, as well as economic efficiency
standpoint.

Public Health Perspectives
From the public health standpoint, AAP associated adverse side effects could
impose a considerable health care burden on a number of children and adolescents.
There are serious adverse side effects reported in AAP users, including obesity,
metabolic syndrome, cardiovascular events, Type II diabetes, and increased mortality. In
spite of the severe health risks, ADHD has been reported as one of the most frequent
conditions for which children and adolescents were prescribed AAPs.8,22,23 Pathak et al.
examined the dispensing pattern of AAPs using a state Medicaid claims data and
reported that ADHD was the most common condition for children and adolescents to be
prescribed with AAPs from 2001 to 2005.8 Also, Cooper et al. reported the same finding
from the National Ambulatory Medical Care Survey and National Hospital Ambulatory
Medical Care Survey.22
In addition to the clinical impact associated with adverse side effects of AAPs,
ADHD patients taking AAPs are at risk of experiencing drug-drug interactions. More
specifically, medication therapy in ADHD usually initiates with stimulants and the
initial stimulant therapy is later augmented with AAPs, or switched to AAPs.24
Therefore, the drug-drug interaction could occur between stimulants and AAPs as they
have opposing mechanisms of action, such that stimulants increase dopamine level and
7

AAPs blocks dopamine receptor activation. For this reason, the concurrent use of the
two medications could potentially mask the underlying chemical imbalance. Moreover,
several studies have reported that not only concurrent use, but switching from one
medication to the other also caused movement disorders such as dyskinesia or extrapyramidal symptoms.25,26

Economic Efficiency Perspective
From the economic efficiency standpoint, AAP use in ADHD is concerning
because a large number of AAPs are possibly misused in the ADHD population. Unlike
most other mental disorders for which medication therapy is the only treatment option,
the ADHD clinical practice guideline recommends behavioral therapy accompanied by
FDA-approved medications.11 Also, it is recommended that prescribers carefully
consider benefit and harm and make sure the use of medication is beneficial. However,
it is not clear whether the use of AAPs in ADHD for symptom control outweighs the
potential harm, because the evidence is limited. Nevertheless, a recent study conducted
by Sikirica et al., shows that approximately one in eight ADHD patients who initiated
medication therapy with a stimulant were prescribed AAPs before trying other FDAapproved medications.24 Sikirica et al., also estimated resource utilization and costs of
stimulant-treated ADHD children who switched to or augmented their stimulant
treatment with atypical antipsychotics compared with non-antipsychotic medications.
Using samples matched based on propensity to receive an AAP, they found that the
AAP cohort had higher mean all-cause and mental health-related costs compared to the
8

non-AAP cohort ($7,407 vs. $5,072; $5,402 vs. $3,054, respectively in 2012 US $; all
P<0.001). Therefore, if AAPs are misused for ADHD, the economic impact for society
will be substantial considering the high costs involved in AAP use and the number of
individuals affected. 8,22,23

F. Systematic review of adverse side effects associated with AAP use in children and
adolescents.
The effectiveness and safety of AAPs are not yet established in children and
adolescents. Prior studies about AAP-related adverse side effects in children and
adolescents are not ADHD-specific. Also, the study design, patient inclusion criteria,
and methodological approaches to control for confounding vary among studies.
Although there are more studies about increased mortality in the elderly population27 or
the increased risk of diabetes/cardiovascular disease in adults,28-30 fewer studies exist in
children and adolescents to evaluate those risks. A majority of studies that are focused
on AAP adverse effects in children and adolescents examined weight gain. Key findings
of selected studies about three major AAP- related side effects, namely weight gain,
Type II diabetes, and cardiovascular event, are summarized in this section.
This literature review is based on the literature from Medline search, with the
Mesh terms of: “child”, “adolescent”, “metabolic syndrome X”, “diabetes mellitus”,
“dyslipidemia”,

“cardiovascular

disease”,

“hypertension”,

“hyperglycemia”,

“overweight”, “obesity”, and “weight gain”. Also, the search was restricted to the Mesh
major topic of “antipsychotic agents/adverse effects”, in order to retrieve articles where
9

the adverse effects are the major focus of the article. All retrieved articles were further
culled by excluding non-English written articles, letters, news and adult population
based studies. i (Figure 1.1) The search was conducted on April 25, 2013.
It should be noted that the search terms that were used in this study may not
capture articles that reported adverse side effects as a secondary outcome. We sought to
search the studies that focused mainly on adverse side effects of AAPs. However, our
search terms potentially miss some of the randomized controlled trials in which drug
effectiveness is the primary outcome, while side effects are reported as well.

Weight Gain
Findings from prior studies are consistent in indicating that children and
adolescents who used AAPs are likely to gain weight. From the Medline search, two
review articles and nine primary studies that specifically focused on AAP-induced
weight gain in children and adolescents were identified. Both review articles observed
significant weight gain related with the AAP use in younger population. 31,32 Original
articles about weight gain associated with AAPs are summarized in Table 1. 4. The
average weight gain among AAP users was 7.45 kg (± 2.33) in 6 months if it is assumed
that the rate of weight gain is consistent over time.33-40 Interestingly, the rate of weight
gain differs by agent according to studies conducted by Fleischhaker et al., which
compared clozapine, olanzapine and risperidone in the follow-ups of 6 weeks and 45
In the Mesh database, “adolescent” refers to a person 13 to 18 years of age. Some papers target
adult population and include study subjects who are age 18 or greater. However, since they
include those with age 18, the paper will include the Mesh term of “adolescent” in addition to
“adult”. Such papers were excluded because those are mainly adult population based.
i

10

weeks.36,37. The average weight gain at the 6 week follow up was the highest in
olanzapine (4.6kg) followed by risperidone (2.8kg) and clozapine (2.5kg). At the 45-week
follow up, olanzapine still showed the highest weight gain (16.2kg) but followed by
clozapine (9.5kg) and risperidone (7.2kg). That is, having olanzapine is associated with
the fastest weight gain throughout the study period (45 weeks), risperidone showed
faster weight gain than clozapine in the short term (6 weeks), but clozapine became
faster in the longer term (45 weeks). Correll et al., also examined agent-specific weight
gains using olanzapine, quetiapine, risperidone, and aripiprazole, compared with a nonuser group.40 In their study, olanzapine was associated with the highest weight gain,
which is consistent with the finding of Fleischhaker et al. In addition to the studies
focusing on children and adolescents, there were three articles that studied agedependent effects.41-43 All three articles concluded that the change in weight was
significantly larger in children and adolescents, compared to adult patients.

Type II Diabetes
There were few clinical studies that examined the association between AAP use
and type II diabetes in children and adolescents. (Table 1. 5.) ii Panagiotopoulos et al.,
conducted a cross-sectional study using laboratory test results to identify type II
diabetes patients and found a significantly higher rate of type II diabetes among the

ii

Because the systematic review search was conducted in April 2013, a retrospective cohort study
published by Bobo et al. in October 2013 was not included in this report. Bobo et al. reported the
three times higher risk of type II diabetes among antipsychotic users compared to other
psychotropic medication users in children and youth 6 to 24 years of age.
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AAP user group, compared to the non-user group.44 However, they did not account for
any confounders in the analysis and it is possible that the higher prevalence of type II
diabetes among the AAP user group is not necessarily associated with AAP use.
McIntyre et al. used a state Medicaid database and adjusted for age, sex and ethnicity in
their retrospective cohort study.45 They reported a statistically significant impact of
multiple AAP use on type II diabetes that was identified using ICD-9-CM (OR: 2.36; 95%
CI: 1.13-4.92). However, their current user design could have overestimated the impact
of AAP on the probability of Type II diabetes development. Current user design is a
study design where the subjects are identified on the basis of current exposure, without
tracking the past exposure. The current user design could introduce bias since the
disease risk factors that may be altered by the study drug cannot be controlled. Andrade
et al., on the other hand, used a new user design and matched samples using propensity
scores in order to adjust for possible selection bias on AAP use.46 They conducted a
retrospective cohort study and compared the AAP new users to non-users, as well as to
antidepressant users (active comparator). While AAP users were more likely to develop
Type II diabetes compared to non-users in unadjusted analysis (IRR: 4.24; 95% CI: 1.958.72), when the two groups were matched using propensity scores, the impact of AAP
became not significant (IRR: 4.47; 95% CI: 0.23-263.82). Also, when they compared AAP
users to antidepressant users, the likelihood of Type II diabetes development was not
significantly different either in unadjusted analysis or propensity score matching
analysis.

12

There were two studies that did not specifically focus on children/adolescents
but looked at the age-stratified relationship.32,47 One of the studies analyzed the US Food
and Drug Administration (FDA) Adverse Event Reporting System (AERS) and they
reported that in the 0-17 years of age group, a 95% likelihood of diabetes-related adverse
events (DRAEs) occurred at least two times more frequently than expected.47 The other
study that examined the age-dependent relationship used the current user study design
and found that the association between diabetes and AAPs use was stronger in younger
patients.32 For patients aged 0-24 years, the impact of clozapine, olanzapine and
risperidone was strongest among all of the age groups (clozapine OR 20.4; 95% CI: 7.554.9, olanzapine OR 8.2; 95% CI:4.4-15.4, risperidone OR 6.1; 95% CI: 3.8-9.7).

Cardiovascular Events
From the Medline search, one article was identified for cardiovascular events
associated with AAP use in children and adolescents. McIntyre et al. conducted a
retrospective cohort study and examined AAP-related cardiovascular events in children
and adolescents at two levels of comparison in a Medicaid population: the primary
comparison was performed between AAP users and non-users and secondary
comparison was performed between single AAP users and multiple AAP users.
Cardiovascular events included ischemic/pulmonary heart disease, arrhythmias and
cardiomegaly.45 The paper reported that the odds of having a cardiovascular event was
significantly higher for multiple AAPs users than single AAP users.

13

G. Need for evidences from well-designed research
Observational studies are useful in examining drug associated side-effects that
require a long-term follow-up. Although there are prior studies providing the evidence
of risks associated with AAPs, the number of studies that attempt to control for
confounding is still limited.
The observed variation in findings in the literature is likely due to different
methods used to avoid confounding and bias. In other words, each study included
different confounders in their analyses and therefore, the impact of AAP use would have
been adjusted differently depending on the strength of correlation between the AAP use
and other confounders. Also, different study designs and methodological approaches
can result in different conclusions. Andrade et al. conducted both adjusting and
matching analysis. In result, the AAP use was shown to have a significant impact on
diabetes development when using the adjusting method, but the association was not
significant in the propensity score matching analysis. The estimates from the two
methods could be different if a selection bias is present in the study design. More
specifically, adjusting controls for other confounders that are associated with treatment
and also with the outcome so that the estimate of treatment reflects the independent
impact of AAP. However, matching attempts to control for potential selection bias in
which the treatment group has a differential impact on the outcome regardless of the
treatment, by selecting samples that are only different in treatment, but otherwise
similar to each other.

14

However, analytical method is not the only explanation for the different
conclusions. Criteria for identifying AAP users could have impacted the findings as well.
For example, McIntyre et al. reported a statistically significant impact of AAP on Type II
diabetes using current user design, but this could make the interpretation of the result
arguable whether the observation of current users yields the unique impact of AAP on
the probability of Type II diabetes development. Because non-randomized studies often
lack detailed historical data on pretreatment information, it is more credible to restrict
the treatment group to new users so that the estimate is more internally valid.

H. Areas of future research
Although it is not specific to the ADHD population, prior studies have warned to
be cautious about using AAPs in children and adolescents due to their adverse effects.
Due to potentially important implications in public health as well as efficient resource
allocation, the use of AAPs in the ADHD population needs to be assessed with a
multidisciplinary approach that examines how the exposure to atypical antipsychotics
clinically affects the young population, and what the economic consequences of the
treatment are. Therefore, my dissertation research will address underlying problems
about AAP utilization, and its implication to ADHD children and adolescents. In chapter
1, detailed backgrounds about ADHD and issues related with AAPs were provided from
literature review. Then, in chapter 2, the national utilization trend of AAPs, off-label
practice, and use in ADHD is examined. The chapter further inspects the trend by payer
source, and regional variations in the US. In chapter 3, as one of the potential adverse
15

effects, the risk of Type II diabetes in pediatric AAP users is estimated. Combined with
chapter 2, the findings of this chapter will suggest the magnitude of risk that is imposed
on the pediatric population in the U.S. While chapters 2 and 3 focus more on AAP
utilization in general and assess the potential impact on ADHD, following chapters
restrict the population specifically to ADHD patients and look into the impact of the
drug on the ADHD specific patient level. Chapter 4 estimates the cost-effectiveness of
AAPs in ADHD from literature review. Then, chapter 5 presents an original study that
compares resource utilization and costs between atypical antipsychotic (AAP) users and
non-AAP users in ADHD.
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Table 1. 1. Core symptoms of ADHD adapted from DSM-IV-TR
Inattention Dimension

Hyperactivity-Impulsivity Dimension
Hyperactivity

Impulsivity
Blurts answers before

Careless mistakes

Fidgety

questions

Unable to stay seated

Difficulty awaiting turn

Moves excessively

Interrupts/intrudes on

(restless)

others

Difficulty sustaining
attention

Seems not to listen

Difficulty engaging in
Fails to finish tasks

leisure activities quietly

Difficulty organizing

"On the go"

Avoid tasks that require
sustained attention

Talks excessively

Loses things
Easily distracted
Forgetful

Source: Clinical practice guideline for the diagnosis, evaluation, and treatment of
attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics
2011;128:1007-22.
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Table 1. 2. FDA-approved ADHD medications

Brand name
Adderall

Oral

Generic
form
available
√

Adderall XR

Oral

√

Dexedrine/Dextrostat

Oral

√

Dexedrine Spansule

Oral

√

Lisdexamfetamine

Vyvanse

Oral

Methylphenidate

Concerta

Oral

Methy ER

Oral

Methylin

Oral

Daytrana

Transdermal

Ritalin

Oral

Ritalin LA

Oral

Ritalin SR

Oral

Metadate CD

Oral

Focalin

Oral

Focalin XR

Oral

Atomoxetine

Strattera

Oral

Extended-release guanfacine

Intuniv

Oral

Extended-release clinidine

Kapvay

Oral

Medication
Mixed amphetamine salts

Dextramphetamine

Dexmethylphenidate
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Route

√

√

√

Table 1. 3. Atypical antipsychotics and FDA-approved indications

Medication
Aripiprazole
Asenapine

FDA indication
Schizophrenia, bipolar I
disorder, adjunctive to
majore depression

Brand
Abilify

Schizophrenia, bipolar
mania

Saphris

Clozapine

Treatment-resistant
schizophrenia

Clozaril

Iloperidone

Schizophrenia

Fanapt

Lurasidone

Schizophrenia

Latuda

Olanzapine

Schizophrenia

Zyprexa

Maleate

Generic form
available

√

Zyprexa
relprevv
Zyprexa zydis
Olanzapine/Fl
uoxetine
Paliperidone

Depressive episodes
associated with bipolar I
disorder, treatment resistant
depression

Symbyax

Schizophrenia

Invega
Invega
sustenna

Quetiapine

Risperidone

Ziprasidone

Schizophrenia, bipolar
mania, bipolar depression

Seroquel
Seroquel XR
Risperdal

Schizophrenia, bipolar I
disorder, autism

√

√

Risperdal
consta

Schizophrenia, bipolar I
disordermajore depression
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Geodon

√

20

21
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Figure 1. 1. Flowchart of review article selection

200 full text articles about antipsychotic agent adverse effects in children/adolescent

Excluded articles

124 Adult studies*, 3 small number samples (n<10), 3
news, 24 letters, 7 non-English written articles, 12 side
effect treatment articles, and 10 side effect mechanism
articles

Weight gain

Type II diabetes

Cardiovascular events

8 Original articles (Table 1. 4),
2 adult-children/adolescent comparison studies,
2 literature reviews

3 Original articles (Table 1. 5)
2 adult-children/adolescent comparison studies

1 Original article**

* In the Mesh database, “adolescent” refers to a person 13 to 18 years of age. Some
papers target adult population and include study subjects who are age 18 or greater.
However, since they include those with age 18, the paper will include the Mesh term of
“adolescent” in addition to “adult”. Such papers were excluded because those are
mainly adult population based.
** The article about the risk of cardiovascular events also reported about Type II diabetes,
and it appears twice in the figure.

Copyright © Minji Sohn 2014
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Chapter 2: National trends in atypical antipsychotics in children and adolescents

A. Background
As a result of the intense marketing campaigns promoting atypical
antipsychotics (AAPs) as a safer alternative (i.e., reducing the risk of side effects like
extrapyramidal symptoms) to conventional antipsychotics, and despite the safety
concerns (i.e., metabolic syndrome, cardiovascular events, or death)3-5 raised by postmarketing studies in adults, AAP use has increased not only for indications approved by
the US Food and Drug Administration (FDA) but also for other conditions.48 In children
and adolescents in the US, AAPs are probably among the most increasingly used classes
of prescription drugs.49,50 In a study using data from three Medicaid programs and one
private managed care organization in the U.S., the total AAPs use for children and
adolescents increased 1.5- to 3-fold between 1996 and 2001.50 Also, medical office visits
including antipsychotic medications for youth patients increased 5-fold between 1993
and 2002.51 However, to the best of our knowledge, previous trend analyses for the
pediatric AAP use have not been updated for more recent years. Also, it would be
essential to understand the current trend of pediatric AAP use and characteristics before
discussing the clinical/economic benefits and costs. Therefore, the purpose of this
chapter is to (1) examine the historic trend of AAP use in the US among 4- to 18- yearold patients, (2) assess the characteristics of AAP use by identifying primary mental
disorders and frequently used AAP agents, and (3) estimate the strength of independent
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association of patient/provider characteristics with AAP prescription among pediatric
(4- to 18- year-old patients) ADHD visits.

B. Materials and methods
Data source
Data sources for this study were the National Ambulatory Medical Care Survey
(NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS). The
NAMCS and NHAMCS are national surveys that collect data on outpatient visits to nonfederal employed, office-based physicians who are primarily engaged in direct patient
care and outpatient departments of non-institutional general and short-stay hospitals.
We intended to estimate the national trend of non-emergent visits that are relevant to an
AAP prescription. For this reason, we did not analyze data collected from hospital
emergency departments and ambulatory surgery centers.
In the NAMCS/NHAMCS data, each visit has information about patient sociodemographics, physician characteristics, diagnoses, and prescription drugs. Up to three
diagnoses were recorded per visit using the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM). The maximum number of drugs that could be
recorded per visit was six during 1995-2002, and it increased to eight in 2003. Following
the National Center for Health Statistics recommendation,52 we included only six firstlisted drugs in most of years (between 1995 and 2010) to avoid overestimating the
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prescribing rate that may be affected by the change in the number of drugs was recorded.
However, five drugs were included in the analysis for the years of 1993 and 1994. iii
The data from 1993 to 2010 were used to compute the annual average rate of
pediatric AAP visits. The data from 2007 to 2010 were combined and analyzed to assess
the characteristics of pediatric AAP visits (i.e., primary mental disorders and frequently
used AAP agents) and to identify predictors of AAP use in pediatric ADHD visits.
Sample weights were applied in all analyses using Stata statistical software, version 12.

Definition of an AAP visit
An outpatient visit was regarded as an AAP visit if one or more following
medications are present: risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole,
paliperidone, asenapine, and iloperiodone. For 1993-2005, the National Center for
Health Statistics (NCHS) provided generic codes were used to identify AAPs. Then,
beginning in 2006, NAMCS/NHAMCS changed the drug identification method by
implementing Multum codes. Also, AAP visit rates for FDA approved indications were
estimated. I defined an AAP visit for FDA approved indication as an AAP visit with a
record of one or more indications that are approved by FDA for any age group at a
given study year. Even if a pediatric patient was prescribed an AAP with an indication
that is only approved for adults, I still considered that as the AAP use for a FDA
The years of 1993 and 1994 had up to five drugs that could be entered. Although the National
Center for Health Statistics recommends using the consistent number of drugs throughout the
study period when performing trend analyses, we considered that the contribution of these two
years to the overall trend analysis was minimal and that including five drugs in 1993-1994 and six
drugs in 1995-2010 in the analyses would not result in overestimation of an actual increase in
prescribing an AAP during 1995-2010.
iii
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approved indication. During 1993-2010, AAPs were approved by FDA for four
conditions iv; (1) schizophrenia (ICD-9-CM, 295), (2) bipolar disorder (ICD-9-CM, 296.0;
296.1; 296.4-296.8), (3) depression (ICD-9-CM, 296.2; 296.3; 300.4; 311.X), and (4) autism
(ICD-9-CM; 299.0). Figure 2. 1 depicts FDA approved indications for each AAP agent
throughout the study period.

National trend of AAP visit (1993-2010)
As the first objective of the study, we examined the national trend of AAP visits
by calculating average AAP visit rates among 4- to 18- year-old patients for each survey
year between 1993 and 2010.
Based on the major events occurred related to AAP use during the period, I
combined survey years and formed three phases in a way that a new phase began when
additional indication was approved by FDA for AAP use. For each phase, the average
visit rate with 95% confidence interval (CI) was calculated. Then, we explored whether
there were newly available AAP agents or additional FDA warnings during each phase.

Mental diagnoses related with AAP visit (2007-2010 combined)
We used three recorded diagnoses of AAP visits to examine (1) whether there
was any mental diagnosis (ICD-9-CM, 290.XX-310.XX) in the visit, (2) if one or more
mental diagnoses were present, whether there was any diagnosis for the FDA approved

Olanzapine was approved for the manifestations of psychoses (ICD-9-CM; 290.XX-299.XX)
between 1996 and 2000. In 2000, the FDA changed the approval for olanzapine to schizophrenia
and bipolar disorder.
iv
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indication (as defined above), and (3) if there were one or more mental diagnoses but
none of FDA approved indications, what was the first-listed mental diagnosis in the visit.
For the mental health visits without an FDA approved indication, the first-listed mental
diagnosis was classified into following categories: (1) psychoses with origin specific to
childhood (“psychoses” hereafter, ICD-9CM, 299.X), (2) disturbances (ICD-9CM, 312.XX;
313), (3) neurotic disorders (ICD-9CM, 300.0X; 300.1X, 300.2X, 300.3; 300.5; 300.8X; 300.9)
and (4) other mental disorders (ICD-9-CM, other codes between 290.XX-310.XX).

Factors associated with an AAP prescription in pediatric ADHD visits (2007-2010 combined)
The data from 2007 to 2010 were combined and analyzed to estimate
independent associations of patient demographic/socioeconomic characteristics (age, sex,
race, region of residence, household income/education level based on ZIP code, and
payer source), physician characteristics (provider type, metropolitan statistical area
located), and patients’ health information (presence of hyperactivity v, number of nonAAP drugs, other comorbidities) with an AAP prescription among pediatric ADHD
visits. A logistic regression model was developed including these covariates vi and odds
ratios with associated 95% confidence intervals were estimated.
Among 4- to- 18-year-old ADHD patient visits during 2007-2010, 4 percent had
missing observations for variables that were based on patient ZIP code, such as median

v

There are two ICD-9-CM codes for ADHD: attention deficit disorder without hyperactivity
(314.00) and attention deficit disorder with hyperactivity (314.01)
vi

Covariates were included in the logistic regression model regardless of its statistical
significance. That is, even if a covariate was not significant at 5% significance level, it was still
controlled in the model.
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household income and percent of Bachelor’s degree or higher. These missing
observations were not included in the analysis. However, I used imputed data for
observations missing a race variable. There were 29 percent missing observations for the
race variable during 2007-2010 and I used NAMCS/NHAMCS provided imputation
values for those missing observations. The method used by NAMCS/NHAMCS for 2007
and 2008 data to impute the race value was based on the patient’s locality (ZIP code or
state/county of residence), physician locality, specialty, or 3-digit ICD-9-CM code for
primary diagnosis. If all failed to assign the race value, the imputation was done based
on a randomly selected record. For 2009 and 2010 data, race was imputed using a modelbased, single, sequential regression imputation method. The model for imputing race is
described in more detail in the 2009-2010 NAMCS/NHAMCS Public Use Data File
Documentation.53

C. Results
National trend of AAP use
From 1993 to 2010, the overall AAP use showed an increasing pattern. (Figure 2.
2) When risperidone became first available in 1993, NAMCS/NHAMCS did not have a
sample visit indicating a pediatric AAP use, as well as in 1994. Starting from 1995, the
rate of AAP prescription increased gradually until 1999. Between 1999 and 2000, the
average AAP visit rate increased more than twice from 0.4 per 100 visits to 0.9 per 100
visits. Then, the increased rate maintained at a stable level until 2002. Then, the average
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rate increased twice again from 2002 to 2003 (from 0.8 per 100 visits to 1.6 per 100 visits),
after which average visit rates showed a more fluctuating pattern.
Based on FDA approvals for additional AAP indication, I combined survey years
and formed three phases: (1) phase I for the 1993-1999 period, (2) phase II for the 20002002 period, and (3) phase III for the 2003-2010 period. More specifically, each phase
begins with a newly approved indication for AAP use. It was observed that the average
visit rates between these phases were statistically different at 5% significance level.
During phase I, the average AAP visit rate was 0.15 per 100 visits (95% CI, 0.1-0.21 per
100 visits). Three AAP agents were available in the market with two FDA approved
indications during the period. Then, the average AAP visit rate increased significantly to
0.81 per 1000 visits (95% CI, 0.54-1.21 per 100 visits) in phase II. During the period, two
additional AAP agents became available (total five agents available in the market). Also,
olanzapine was first approved for bipolar disorder in 2000 and it remained as the only
AAP agent approved for the indication until 2002. In phase III, the average AAP visit
rate was 1.59 per 100 visits (95% CI 1.37-1.83). During phase III, three new AAP agents
became available (total eight agents available in the market) and the FDA approved
AAPs for more indications including depression and autism. Moreover, the pediatric
AAP use was first approved during this period. vii

vii

Readers should be reminded that I did not restrict the definition of FDA approved AAP
indication into specific age group (i.e., even if a pediatric patient was prescribed an AAP with an
indication that is only approved for adults, I still considered that as the AAP use for FDA
approved indication). I identified additionally approved indications age-specifically (adult and
pediatric) only for the purpose of exploring events occurred during each phase.
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Throughout the study period, a majority of AAP visits did not include a
diagnosis for FDA approved indications (referred to as “off-indication” in the Figure 2.
2). The off-indication visits accounted for approximately 86 percent of pediatric AAP
visits during 1995-2003 and 71 percent during 2004-2010. A statistically significant
increase for FDA approved AAP use was observed between 2003 and 2004, when three
AAP agents including aripiprazole, quetiapine, and ziprasidone were approved for
bipolar disorder in addition to their previously approved indication, schizophrenia.

Mental diagnoses related with AAP visit
The estimated number of total outpatient AAP visits among 4- to 18- year-old
patients during 2007-2010 was 8,380,436 (weighted count) which accounted for
approximately 2 percent of total pediatric outpatient visits in the U.S.. Of those, 34%
visits included one or more diagnoses of FDA approved indications. (Figure 2. 3) Within
this group, a majority of visits had diagnoses of bipolar disorder or depression (16% or
14% of total pediatric AAP visits, respectively), followed by autism and schizophrenia (5%
or 1% of total pediatric AAP visits, respectively). Approximately 2% of total pediatric
AAP visits had two of more diagnoses of FDA approved indications.
Among the pediatric AAP visits without any FDA approved indications, ADHD
was the most common primary mental diagnosis (24% of total pediatric AAP visits),
followed by psychoses (14% of total pediatric AAP visits). Disturbances and neurotic
disorders took up about 5% of total pediatric AAP visits respectively. Approximately 15%
of total pediatric AAP visits did not include any mental disorder diagnosis.
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Frequently prescribed atypical antipsychotics
Of the 8,380,436 total pediatric AAP visits, a majority of visits prescribed
risperidone, aripiprazole or quetiapine (35%, 32%, or 18% of total pediatric AAP visits)
(Figure 2. 4). A smaller proportion of visits prescribed ziprasidone, olanzapine, or
paliperidone (6%, 5%, or 1% of total pediatric AAP visits). Approximately 3% of total
pediatric AAP visits prescribed two or more AAPs.

Factors associated with an AAP prescription in pediatric ADHD visits
During 2007-2010, the total number of pediatric ADHD visits was estimated to be
31,501,209. Of those, 12% included one or more AAP prescriptions (weighted count:
3,763,296). Baseline characteristics of pediatric ADHD visits are summarized in Table 2.
1. Between AAP visits and non-AAP visits, patient demographics and health care
provider characteristics were not statistically significantly different. However,
significantly larger proportion of AAP visits had Medicaid as the primary source of
payment. In terms of ADHD characteristics, AAP visits were more likely to have
attention deficit disorder with hyperactivity compared to those without hyperactivity.
Also, AAP visits had more drugs (other than AAPs) prescribed compared to non-AAP
visits. Baseline comorbidity profile was also different in a way that AAP visits had more
comorbid conditions including FDA approved AAP indications, psychoses, neurotic
disorder, disturbance and diabetes.

32

In the logistic regression analysis, having Medicaid as the primary payment
source, more prescription medications, and comorbid mental disorders including FDA
approved AAP indications, psychoses, neurotic disorder, disturbance or diabetes
significantly increased the likelihood of having an AAP prescription in a pediatric
ADHD visit. (Table 2. 2) However, having comorbid obesity decreased the likelihood of
having an AAP prescription.

D. Discussion
The purpose of this study was to examine the national trend of pediatric AAP
use in an outpatient health care setting in the US. The average AAP visit rates were
estimated each year between 1993 and 2010, and events related with AAP use were
explored during the period. Then, mental diagnoses related to AAP prescription and
frequently used AAP agents were assessed for the period of 2007-2010. Lastly, we
estimated the strength of independent association of patient/provider characteristics
with AAP prescription among pediatric ADHD visits.
From 1993 and 2010, the overall visit rates of AAP prescription in pediatric
outpatient visits showed an increasing pattern. There was approximately 5-fold
significant increase from phase I (1993-1999) to phase II (2000-2002) and two-fold
significant increase from phase II to phase III (2003-2010). When comparing with AAP
related events occurred during each phase, as more AAP agents became available and
more AAP indications were approved by FDA, the AAP visit rates also increased
(Figure 2. 2). Also, it appeared that sudden increases of AAP visit rates were associated
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with an FDA approval for an additional AAP indication. More specifically, in all AAP
drug approval processes during 1993-2010, all AAP agents became initially available for
schizophrenia. Years later, some AAPs changed labels by including additional
indications including bipolar disorder, depression, and autism. Interestingly, bipolar
disorder was first approved to be treated with olanzapine among AAP agents in 2000,
and in the same year, there was an abrupt increase in AAP visit rates, which eventually
initiated the next phase. Olanzapine was first approved for treatment of depression in
2003, and there was another abrupt increase in AAP visit rates leading to the next phase
in the same year. Although it was less abrupt, when autism was first approved to be
treated with risperidone in 2006, the AAP visits also showed the highest rate since the
first depression approval in 2003. However, it is hard to argue that such increased visits
are mostly to treat the additionally approved indication. For example, from phase I to
phase II, AAP visits for FDA approved indications increased only 0.09 per 100 pediatric
outpatient visits, while AAP visits for off-indication uses increased 0.57 per 100 pediatric
outpatient visits. Similarly, from phase II to phase III, the increase in visits for offindication usage was larger than for FDA approved indication. One of the plausible
explanations for this phenomenon might be that having an approval for additional AAP
indication impacted the AAP therapy decision-making process in a way that an AAP
agent was thought to be also effective for conditions other than currently approved
indications. However, my trend analysis does not control for any covariates and
therefore, further investigation using carefully designed models is needed to clarify the
association of a certain event with AAP visit rates.
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My analysis for identifying mental diagnoses that are seemingly related with
AAP prescription revealed that approximately 66 percent of total pediatric AAP visits
did not include a diagnosis for FDA approved indications between 2007 and 2010. Of
those, ADHD was the most common primary mental diagnosis. This finding is
consistent with several previous studies that examined pediatric AAP use. Pathak et al.
examined the dispensing pattern of AAPs using Arkansas Medicaid claims data and
reported that ADHD was the most common condition for children and adolescents to be
prescribed with AAPs between 2001 and 2005.8 Cooper et al. reported the same finding
from the NAMCS/NHAMCS data between 1995 and 2002.22 Also, approximately 15
percent of total pediatric AAP visits did not include any mental diagnosis. A similar
problem was previously concerned by Staller et al. who reported that 77 percent of
outpatient antipsychotic visits by 18 year-old or younger patients did not have a mental
diagnosis. They collected medical and prescription data from eight outpatient clinics in
central New York in 2002. The fact that they had a much higher proportion of
psychiatric visits without a mental diagnosis than my study could be explained a
number of factors including different sampling method, different number of recorded
diagnoses, or different inclusion criteria in defining antipsychotic visits. Nonetheless,
both studies raise an important issue about current antipsychotic prescription pattern
which suggests that antipsychotic medications could be frequently misused in pediatric
population.
From my logistic regression model estimating the association between several
factors and AAP prescription among pediatric ADHD visits, patient demographics and
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health care provider characteristics did not show a significant association with AAP
prescription. Instead, patients’ medical profiles showed much stronger associations with
AAP prescription. More specifically, having more co-prescribed medications (i.e., other
than AAPs) and comorbid mental disorders including FDA approved AAP indications,
psychoses, neurotic disorder and disturbance increased the likelihood of having an AAP
prescription. This result indicates that an AAP is more likely to be prescribed to ADHD
patients when multiple health conditions are present, controlling for other patient/health
care provider characteristics. The result of Medicaid being a significant factor could be
also explained with this result, since chronic illness and other health risk factors are
more prevalent among Medicaid enrollees compared to those who are covered by a
private insurance. 54-56
There are some limitations that should be noted. First, the survey may not
capture sufficient information to estimate the AAP visit rates and characteristics of visits.
I used six first-listed medications and three diagnosis codes for the study period.
However,

such

limited

availability

of

medical/pharmacy

records

may

have

misrepresented the true estimates in the study. For example, it is possible that some
AAP treated patients had a severe physical illness in addition to mental disorders, and
due to the limited space for the number of diagnosis codes on the survey form, their
health care providers were only able to record diagnoses for physical illness. In this case,
the visit data would have been categorized as an AAP visit with no mental disorder
diagnosis code, although the visit actually had a mental disorder diagnosis. Second,
NAMCS/MHAMCS for 1993-2010 were designed to obtain the national/regional estimate
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of outpatient health care service measures. However, due to insufficient sample size,
state-level estimates are usually unreliable. For this reason, we were unable to
independently assess the association of states with the AAP prescription among
pediatric ADHD visits. Third, due to the nature of micro visit level data, the temporal
relationship of explanatory variables and AAP prescription was not identifiable. In other
words, it is not possible to conclude that having comorbid conditions triggered the AAP
use. Instead, we only know that comorbidities are associated with AAP use. Fourth,
variables of obesity, diabetes and cardiovascular disease in our logistic regression model
had only few observations, making the estimated values unreliable. Especially, the
variable of cardiovascular disease was dropped from the estimation, because there was
no variability between AAP prescription and cardiovascular disease. This is probably
due to the small number of observations in the variable of cardiovascular disease.
In conclusion, I showed that outpatient visits including an AAP among 4- to 18year-old patients has significantly increased between 1993 and 2010 in the US, and over
65 percent of those visits did not have diagnoses for FDA approved AAP indications.
During 2007-2010, the most common mental disorder was ADHD, accounting for 24
percent of total pediatric AAP visits. Among visits with ADHD diagnosis, those with
comorbid mental disorders such as psychoses, neurotic disorder and disturbance were
more likely to have an AAP prescription.
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Figure 2. 2. Atypical antipsychotic use for children and adolescents (ages 4-18)
Rate per 100 outpatient visits

2.5
2

FDA approved indication

Off-indication

1.5
1

0.5
0

Phase I
Newly available
AAP agent

Newly approved
indication (adult)

Phase II

Phase III

Phase I
risperidone,
olanzapine,
quetiapine

Phase II
ziprasidone,
aripiprozole

Phase III
paliperidone, asenapine,
iloperidone

schizophrenia,
manifestations of
psychoses*

bipolar I
disorder

depression

Newly approved
indication
(pediatric)

schizophrenia, bipolar I
disorder, depression,
autism

FDA warning

metabolic syndrome,
increased death in
elderly dementia patients

*Olanzapine was approved for the manifestations of psychoses in 1996-2000. Since 2000,
olanzapine has been approved for schizophrenia and bipolar I disorder (adult).
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Figure 2. 3. Mental diagnoses related with AAP visits

Disturbance
5%

Other mental
disorders
Neurotic
3%
disorders
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FDA approved
indications
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Psychoses
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No mental
disorder
diagnosis
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Figure 2. 4. Frequently used AAP agents

Paliperidone
1%
Olanzapine
5%
Ziprasidone
6%

Two or more
AAPs
3%

Risperidone
35%

Quetiapine
18%

Aripiprazole
32%
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Table 2. 1. Baseline characteristics of pediatric ADHD visits*
AAP visits (N=3,763)
Baseline Characteristics

N

%

Non AAP visits (N=27,738)
N

Age
Pre-school child (age 4-5)**
179
4.76
1,213
Elementary child (age 6-11)**
2,026
53.84
17,081
Adolescent (age 12-18)**
1,558
41.40
9,445
Sex
Male
2,768
73.56
19,587
Female
995
26.44
8,151
Race
White
2,948
78.34
22,427
Black
654
17.37
4,289
Other
162
4.30
1,021
Region of residence
Northeast
726
19.28
4,876
Midwest
896
23.82
7,160
South
1,484
39.43
11,011
West
657
17.46
4,690
Median household income in patient’s zip code
Quartile 1
1,086
28.85
5,886
Quartile 2
859
22.84
8,292
Quartile 3
792
21.05
6,106
Quartile 4
1,026
27.26
7,454
Percent population with Bachelor’s degree or higher in patient’s zip code
Quartile 1
1,074
28.55
7,648
Quartile 2
859
27.22
8,292
Quartile 3
792
18.62
6,106
Quartile 4
1,026
25.61
7,454
Metropolitan statistical area
No
487
12.93
5,542
Yes
3,277
87.07
22,195
Payer source
Private
1,533
40.75
14,726
Medicaid
1,976
52.50
10,593
Self-pay
296
7.87
1,706
Other
1,690
5.45
204
Mental health provider
No
1,103
94.79
26,635
Yes
196
5.21
1,103
Attention deficit disorder with hyperactivity
No
132
41.24
4,040
Yes
3,632
58.76
23,698
Number of non-AAP prescribed (different generic names)
0
322
8.56
3,417
1
747
19.86
13,180
2
1,058
28.11
5,607
3
836
22.22
3,152
4+
800
21.25
2,382
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p Value

%
4.37
61.58
34.05

0.867
0.085
0.089

70.62
29.38

0.498
0.498

80.85
15.46
3.68

0.449
0.507
0.744

17.58
25.81
39.70
16.91

0.681
0.700
0.969
0.916

21.22
29.89
22.01
26.87

0.160
0.067
0.837
0.942

27.57
22.52
26.19
23.71

0.853
0.181
0.105
0.672

19.98
80.02

0.248
0.248

53.09
38.19
6.15
6.09

0.035
0.013
0.610
0.800

96.02
3.98

0.341
0.341

44.75
55.25

0.010
0.010

12.32
47.52
20.21
11.36
8.59

0.138
<0.001
0.007
0.001
<0.001

Table 2. 1. Baseline characteristics of pediatric ADHD visits* - cont’d
AAP visits (N=3,763)
Baseline Characteristics
Comorbidities†
FDA approved indications
Psychoses
Neurotic disorder
Adjustment disorder
Disturbance
Developmental disorder
Obesity
Diabetes
Cardiovascular disease

N

%
970
321
466
88
886
177
2
7
0

25.77
8.53
12.39
2.33
23.55
4.70
0.04
0.18
0.00

Non AAP visits (N=27,738)
N

p Value

%
2,304
547
1,316
435
1,769
799
371
4
10

8.31
1.97
4.75
1.57
6.38
2.88
1.34
0.01
0.04

<0.001
<0.001
0.001
0.304
<0.001
0.358
<0.001
0.008
0.611

*Data are given as weighted count of visits and percentage.
**These variables were tested as binary variables. That is, instead of testing as a single age variable
with three categories, the three categories were tested individually as binary variables.
†These variables are not mutually exclusive.
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Table 2. 2. Predictors of atypical antipsychotic prescription
Covariates

Odds ratio

95% Confidence interval

Age
Pre-school child (age 4-5)
Reference
Elementary child (age 6-11)
0.86
Adolescent (age 12-18)
1.11
Sex
Male
Reference
Female
0.81
Race
White
Reference
Black
0.86
Others
2.05
Region of residence
Northeast
Reference
Midwest
0.84
West
0.84
South
0.90
Median household income in patient’s zip code

0.35-2.09
0.49-2.53

0.51-1.29

0.48-1.55
0.77-5.43

0.40-1.75
0.38-1.84
0.43-1.89

Quartile 1
Quartile 2

Reference
0.65

0.39-1.10

Quartile 3
Quartile 4

0.79
0.93

0.38-1.65
0.39-2.24

Percent population with Bachelor’s degree or higher in patient’s zip code
Quartile 1
Reference
Quartile 2
Quartile 3
Quartile 4
Metropolitan statistical area
Yes
No

1.31
0.77

0.73-2.33
0.31-1.88

1.02

0.41-2.50

Reference
0.52

0.21-1.30

Payer source
Private
Reference
Medicaid
1.66*
Self-pay
1.19
Other
1.08
Mental health provider
No
Reference
Yes
0.77
Attention deficit disorder with hyperactivity
No
Reference
Yes
3.00
Number of non-AAP prescribed (different generic names)
0
Reference
1
0.94

1.01-2.75
0.29-4.94
0.38-3.09

0.31-1.92

0.75-11.93

0.58-1.52

2
3

2.60*
3.06*

1.38-4.90
1.48-6.32

4+

4.48*

2.08-9.64
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Table 2. 2. Predictors of atypical antipsychotic prescription – cont’d
Covariates
Mental Comorbidities
FDA approved indications
Psychoses
Neurotic disorder
Adjustment disorder
Disturbance
Developmental disorder
Physical Comorbidities‡
Obesity
Diabetes
Cardiovascular disease

Odds ratio

95% Confidence interval

Reference
3.34*
2.67*
1.21
3.60*
1.81
0.03
14.21*
dropped†

1.35-8.26
1.27-5.61
0.57-2.58
1.94-6.69
0.71-4.63
0.57-0.19
1.77-114.28

†The variable of cardiovascular disease was dropped because it predicted no AAP use
(AAP=0) perfectly.
‡These variables are mutually exclusive.
*Significant at 5% significance level.
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Chapter 3: The Risk of Developing Type II Diabetes in Atypical Antipsychotic Users
among Children and Adolescents

A. Background
The increase in pediatric AAP use is concerning considering the potential risk of
developing chronic conditions suggested by previous studies, such as obesity31,34,35,38-40 or
type II diabetes (T2DM) in children and adolescents taking these drugs.45,46,57 While
several post-marketing studies examined weight gain and obesity and provided solid
support for the risk, the evidence regarding the risk of T2DM is still limited in younger
populations. Although there are plausible mechanisms to support the hypothesized risk
for T2DM,

58,59

several prior studies evaluating the relationship between AAP use and

diabetes in children and adolescents failed to discriminate between type I and II DM46,
thus resulting in an underestimation of the true effect.60 A recent study evaluated this
specific AAPs-T2DM relationship, but the study population was restricted to a single
state Medicaid population.57 These findings from a single state Medicaid program may
not be generalizable to a broader population.55 Therefore, the purpose of this paper is to
estimate the risk of developing T2DM for children and adolescents who are prescribed
an AAP, using nationally representative health care claims data in the U.S.

B. Materials and methods
Data Source and Study Population
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Through a new user design approach,61 we assembled a retrospective cohort of
children and adolescents using enrollment files, medical and pharmacy claims data from
the i3 Invision Data Mart (IVDM). These data contain information for a de-identified,
nationally representative sample of 15 million commercially insured and Medicaid
managed care patients. Dependents between the ages of 4 to 18 at index date (described
below), who were continuously enrolled between January 1, 2007 and December 31,
2009, were considered for this study.

Exposure
Our study compared an AAP user to a similar group of subjects with no
exposure to AAP (non-users). Subjects were considered to be exposed to an AAP if they
had at least one prescription for any of the available AAPs, which include aripiprazole,
olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone. AAP users were
classified as incident or new users (AAP users, hereafter) and included in the analysis if
they met all of the following eligibility criteria: (1) initial dispensing date of an AAP
(defined as the index date) was preceded by a minimum of six months of continuous
enrollment in the health plan (i.e., pre-index period); (2) did not have prescriptions for
typical antipsychotics during the six months of the pre-index period; (3) had no history
of type I or type II diabetes during the six months pre-index period; (4) had evidence of
resource utilization in the database (i.e., at least one claim of any type during the preindex period). This requirement was made to exclude individuals with multiple health
insurance (i.e., a child whose parents hold multiple health insurance) and made claims
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primarily to another plan other than the one used in this paper, thus to prevent
misclassification due to out-of-insurance service utilization. For the comparison group of
non-users, index dates were randomly assigned based on the distribution of time to
AAP initiation after January 1, 2007 in the AAP treated group. With the randomly
assigned index date, the same sample selection criteria described above for the AAP
treated group (except for AAP prescription) were applied to the non-user group A flow
diagram describing the identification process for the groups included in the analyses is
depicted in Figure 3. 1.
The follow-up time for each subject started on the index date and was extended
until the earliest of (1) T2DM onset, or (2) the end of the study period. This approach
was intended in order to emulate an intention-to-treat analysis similar to randomized
controlled trials.

Outcome
The outcome of interest in our study was new-onset T2DM and was identified
using medical and pharmacy claims and following the algorithm developed by Bobo et
al. (2012).62 We used International Classification of Diseases, 9th Clinical Modification
(ICD-9-CM) diagnosis codes (250; 250.0; 250.1; 250.2; 250.3; 250.9) and National Drug
Codes (NDC) for anti-diabetic medications (insulin, insulin adjuncts, alpha-glucosidase
inhibitor, amylin analogs, meglitinides, sulfonylureas, and thiazolidinediones) to
identify diabetes-related medical/pharmacy care encounters. In order to classify a
patient as having T2DM, we required (1) a hospital discharge with a primary diagnosis
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code for T2DM as described above, or (2) a combination of at least 2 diabetes-related
medical and/or pharmacy claims. When only prescription claims indicated diabetes,
T2DM was further separated from type I diabetes by excluding those with an insulin
prescription with no prescriptions for oral anti-diabetic medication. The date of onset for
T2DM was determined as the date of the first medical/pharmacy care encounter related
to T2DM. However, if a diabetes-related laboratory procedure (i.e., HbA1c, islet cell
antibody test, insulin RIA, or metabolic panel) was performed within 30 days before the
first diabetes-related medical/pharmacy care encounter, the date of the procedure was
considered as the date of T2DM onset.

Covariates
To control for potential selection bias and confounding, non-users were matched
to AAP users using the propensity score (PS) matching method. The PS for each resident
was estimated through logistic regression as the probability of starting AAP treatment
during our study period, based on their baseline characteristics. We used causal
diagrams63,64 to select important covariates for inclusion in the logistic regression model;
specifically, the following covariates were included: age, sex, race, geographic region,
household income, the year of index date, and the health care utilization intensity and
medical history during the pre-index period. Health care utilization intensity was
measured by four variables: the number of hospitalizations, the number of emergency
room (ER) visits, the number of outpatient services, and the number of filled
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prescriptions with different generic names. Medical history was measured through other
medications used (i.e., benzodiazepines and antidepressants), as well as comorbidities
(pregnancy, obesity, and cardiovascular diseases).

Analysis
Baseline characteristics of AAP users and non-users were compared and tested
before and after PS matching using standardized differences.65,66 Using PS, up to four
non-users were matched to every AAP new user. The propensity to receive an AAP was
estimated through unconditional logistic regression and the greedy matching
algorithm67 with calipers equal to 0.2 of the standard deviation of the logit of the
propensity score was used for matching.68
The rates of developing T2DM in the AAP-treated group and control group were
estimated and compared using the Kaplan-Meier (KM) estimator. Cox proportional
hazard regression was performed to estimate the risk of T2DM associated with AAP
initiation. We regarded that the proportional hazards assumption was not violated
because no evidence of interaction between AAP use and time was observed. (HR 0.75;
P=0.223).

C. Results
Baseline characteristics of non-matched samples
A total of 403,345 children and adolescents met our inclusion criteria. Among
those, 6,510 individuals were new AAP users. A majority of AAP users received
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risperidone (n=2608; 40.1%), aripiprazole (n=2044; 31.4%) or quetiapine (n=1439, 22.1%).
Relatively small proportion of AAP users received olanzapine (n=239, 3.7%), ziprasidone
(n=168, 2.6%) or paliperidone (n=50, 0.8%). There were 38 (0.6%) individuals who
received two AAP agents on the index date. Other baseline characteristics before
matching are summarized in Table 3. 1. In the non-matched sample, AAP users were
more likely to be adolescents (ages 12-18) and male than non-users. On average, the
annual household income was lower for AAP users. Also, the AAP users showed a
higher level of health care utilization during the six month pre-index period, with
respect to the number of outpatient service visits, hospitalizations, ER visits, and filled
prescriptions. The baseline comorbidities and drug use profiles also showed large
differences between the two groups in several respects: AAP users evinced higher
prevalence rates of obesity and cardiovascular disease. Also, they showed a higher rate
of use for benzodiazepines or antidepressants.

Calculation of propensity scores
The logistic regression model to evaluate AAP utilization is described in Table 3.
2. The results indicate that older patients were more likely to receive an AAP. Female
patients were less likely to receive an AAP compared to male patients. Also, western
regions of the US were more likely to use an AAP compared to northeastern regions.
Annual household income was significantly associated with AAP use: the propensity to
receive an AAP decreased as the level of household income increased (Table 3. 2). The
higher level of health care utilization measured in the number of outpatient service visits,
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hospitalizations, and prescriptions significantly increased the propensity to receive an
AAP. The c-statistic was 0.876, indicating a good predictive accuracy of the logistic
regression model.

Baseline characteristics of propensity score-matched sample
The final study sample after PS matching consisted of 6,236 incident AAP users
and 22,080 non-users. The characteristics of matched samples are summarized in Table 2.
1 (right). In this matched sample, AAP new users and matched non-users were balanced
on all of the characteristics included in the PS model (standardized differences were
smaller than 5%). Figure 3. 2 shows the kernel density estimates of the PS distribution
between the two groups. The upper panel is depicting the distribution for the nonmatched sample, while the lower panel represents the matched sample showing the
similarity between the two groups after PS matching.

The Risk of Type II Diabetes
The follow-up schedule was very similar between AAP user and non-user
groups. In each group, the mean follow-up time was 1.3 (± 0.7) years with the minimum
of 0 days and the maximum of 2.5 years. The total follow-up time was 8,161 personyears in the AAP user group, and 28,792 person-years in the non-user group. During the
follow-up, a total of 64 subjects developed T2DM, 27 in the AAP user group (33.1 cases
per 10,000 person-years), and 37 in the non-user group (12.9 cases per 10,000 personyears).
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The rate of developing T2DM in the matched sample is represented using the
Kaplan-Meier (KM) estimator (Figure 3. 3). The risk difference between two groups
appeared at approximately 4 months after the index date, and it increased rapidly
between 4 months and 6 months after the index date. After 6 months, the risk difference
was almost constant until the end of the follow-up. The estimated risk of T2DM was
twice higher in AAP users than non-users in the propensity score matched sample (HR
2.18; 95% CI 1.45-3.29).

D. Discussion
The purpose of this study was to examine the association between AAP initiation
and T2DM in children and adolescents. We found that initiation of AAP medication
increased the risk of developing T2DM about two-fold for those between the ages of 4
and 18. While T2DM is known to develop slowly over months and years, the fact that
noticeable risk differences between AAP-treated and comparison groups emerged
between 4 and 6 months is striking. This result is in good agreement with a recent study
published by Bobo and collaborators.57 They conducted a retrospective cohort study for
children and youth, using Tennessee Medicaid health care claims data and reported a
three-fold higher risk of T2DM imposed on antipsychotic medication users (both typical
and atypical), compared to propensity score-matched users of other psychotropic drugs.
Our observation on the probability of developing T2DM during the course of the followup assessment (Kaplan-Meier Curve) is very similar to the result reported in this paper
(Figure 3. 2). For example, at the 20 months (600 days) follow-up the probability of
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T2DM is approximately 0.004 for treatment group, and 0.002 for control group in both
studies. The fact that the point estimate of the hazard ratio reported by Bobo et al. is
different from what we found in our study is likely due to differences in study design,
specifically (1) different follow-up periods (longer for Bobo et al.) and/or (2) study
population (Tennessee Medicaid vs US commercially insured). Another study
previously conducted by Andrade et al. concerned the risk of diabetes associated with
antipsychotic medication use in children and adolescents (ages of 5 to 18).46 They used a
large diverse cohort from Health Maintenance Organization (HMO) databases and did
not find a significant association between AAPs and diabetes in propensity score
matched samples. One of the major differences between our study design and theirs was
the inclusion of type I diabetes in study outcomes. However, a majority of diabetes
patients in children are likely to be type I60 and the concerns about AAP adverse side
effects are often associated with type II.58,59 Therefore, including type I diabetes in an
outcome could have attenuated the risk of AAPs in their study.
In our propensity score matched cohort, a majority of individuals were
adolescents with ages between 12 and 18 (61%), male (63%), and white (78%).
Approximately 47% resided in the south region of the US and more than half of the
sample belonged to households with an annual income greater than $60,000. During the
6 month pre-index period, 86% have not been hospitalized and 98% have not visited ER.
Also, 5% used benzodiazepine and 31% used antidepressant during the period. These
factors could have affected results and need be taken into account when implementing
the findings of this paper.
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It should be noted that the individuals who were identified as having new-onset
T2DM are subject to a potential misclassification. The algorithm we adopted for this
study was developed from a Tennessee Medicaid program, and it is possible that the
algorithm did not effectively identify true T2DM cases in our database. If diabetes
management or diabetes related claim filing process vary largely by the payer source or
geographical regions, it may affect our conclusion about the impact of AAP on T2DM.
Another limitation of our study is a relatively short follow-up. The longest possible
follow-up period in this paper was 2.5 years and the follow-up term does not adequately
capture the longer-term impact of AAPs on T2DM. Also, the small number of new-onset
T2DM cases limited our ability to assess the differential impact of AAPs on different
strata such as patient demographics and socioeconomic factors.
Having non-users as the comparison group might have overestimated the risk of
T2DM for AAP users because AAP users are more likely to be monitored for T2DM than
non-users. However, to minimize potential differences in monitoring between the two
cohorts, we included non-users who had similar health conditions to AAP users during
the pre-index period in the analysis. Moreover, that our study reports similar findings to
previous studies supports the reliability of our study design.
Although it is not the primary interest for our paper, our logistic regression
model revealed important factors associated with AAP use. (Table 3. 2) First, female
patients were less likely to receive an AAP compared to male patients (OR 0.54; 95% CI
0.51-0.57). This is consistent with the national trend, in which female patients are
outnumbered by male patients in children and adolescent psychiatric services.69
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Secondly, the propensity of a patient to receive an AAP decreased gradually as the
household income increased. In other words, if a patient was from a high-income family,
the patient was less likely to use an AAP. This finding has an important implication
about the role of one’s socioeconomic status that affects the exposure to an AAP.
Our study adds strong evidence to the existing literature and overcomes some of
the limitations of previous research. First, our report critically examined patients who
possessed a commercial health care plan within the US, who were either commercially
insured or enrolled in a Medicaid managed care plan. This consideration cannot be
understated, because commercial insurance and Medicaid are the two largest payers of
mental health services in the United States.70 Therefore, the findings of this paper can be
more generalizable to a larger population. Second, we sought to avoid the bias by
matching subjects based on their propensity to receive an AAP. Before matching, there
was a considerable difference observed in baseline characteristics between AAP users
and non-users. Atypical antipsychotic users were more likely to be obese and receive
intense health care services such as hospitalizations and ER visits. (Table 3. 1, left) This
suggests the presence of potential selection bias in the non-matched cohort, in which
AAP users had inherently higher risk of developing a chronic illness including T2DM
than non-users before they were exposed to an AAP. In our propensity score matched
cohort, baseline characteristics were much similar between AAP users and non-users.
In conclusion, we found that children and adolescents who use an AAP
medication had a two times higher risk of developing T2DM within 6 months of
initiating medication when compared to propensity score matched non-users from
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nationally representative health care claims in the U.S. This raises questions about
continued AAP use in children and adolescents. Considering that T2DM is a chronic
condition that may persist the rest of a person’s life, its risk that is imposed on children
and adolescents could outweigh the benefit of AAP therapy in some patients.
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Figure 3. 1. Sample selection flowchart
Patients (4 ≤ Age ≤ 18) who were continuously enrolled for three years
N = 669,253
Excluded:
1. Less than 6 months between enrollment and the
initial atypical antipsychotic dispensing date
(N=9,163)
2. No claims made during 6 month pre-index period
(N=254,737)
3. Having conventional antipsychotics prescription
during 6 month pre-index period. (N=358)
4. Having type I or II diabetes (diagnosis,
prescriptions) during 6 month pre-index period.
(N=1,650)

Study population before propensity score matching
N = 403,345
AAP users before matching

Non-users before matching

N = 6,510

N = 396,835

AAP users after matching

Non-users after matching

N = 6,236

N = 22,080
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Table 3. 1. Baseline characteristics
Before Matching
Baseline
Characteristics

AAP users
(N=6,510)

After Matching

Non-users
(N=396,835)

AAP users
(N=6,236)

Non-users
(N=22,080)

%

d*

14.6

0.380

245

3.9

1,056

4.8

0.018

6-11
2,023 31.1
164,612
41.5 0.218
12-18
4,241 65.2
174,430
44.0 0.436
Sex
Male
3,978 61.1
203,505
51.3 0.199
Female
2,532 38.9
193,330
48.7 0.199
Race
White
5,126 78.7
297,885
75.1 0.087
Black
288
4.4
15,199
3.8 0.030
Hispanic
431
6.6
34,211
8.6 0.075
Others
617
9.5
46,812
11.8 0.075
Region of residence
Northeast
712 10.9
48,113
12.1 0.037
Midwest
1,731 26.6
102,996
26.0 0.014
South
3,074 47.2
190,671
48.1 0.017
West
993 15.3
54,942
13.9 0.040
Annual household income
≤ $29,999
207
3.2
10,152
2.6 0.037
$30,000-39,999
364
5.6
17,593
4.4 0.053
$40,000-49,999
585
9.0
32,271
8.1 0.031
$50,000-59,999
596
9.2
35,877
9.0 0.004
$60,000-74,999
790 12.1
51,644
13.0 0.027
$75,000-99,999
1,170 18.0
81,702
20.6 0.066
≥ $100,000
1,563 24.0
115,304
29.1 0.114
Number of outpatient service visits
0-5
2,357 36.2
330,942
83.4 1.098
6+
4,153 63.8
65,893
16.6 1.098
Number of drugs prescribed (difference generic name drugs)
0-3
3,045 46.8
326,225
82.2 0.797
4+
3,465 53.2
70,610
17.8 0.797
Number of hospitalizations
0
5,214 80.1
392,254
98.9 0.642
1-3
1,273 19.6
4,500
1.1 0.635
4+
23
0.4
81
0.0 0.077
Number of ER visits
0
6,413 98.5
393,944
99.3 0.073
1+
97
1.5
2,891
0.7 0.073
Baseline comorbidities and drug use
Obesity
157
2.4
4,086
1.0 0.106
Cardiovascular
259
4.0
4,504
1.1 0.181
Pregnancy
9
0.1
336
0.1 0.016
Benzodiazepine
460
7.1
2,764
0.7 0.334
Antidepressant
2,648 40.7
9,439
2.4 1.053

1,994
3,997

32.0
64.1

7,721
13,303

35.0
60.3

0.024
0.031

3,802
2,434

61.0
39.0

13,901
8,179

63.0
37.0

0.030
0.030

4,910
275
414
592

78.7
4.4
6.6
9.5

17,274
976
1,494
2,087

78.2
4.4
6.8
9.5

0.008
0.001
0.001
0.003

690
1,647
2,944
955

11.1
26.4
47.2
15.3

2,357
5,826
10,430
3,464

10.7
26.4
47.2
15.7

0.015
0.007
0.006
0.013

193
348
558
570
757
1,133
1,520

3.1
5.6
9.0
9.1
12.1
18.2
24.4

764
1,350
1,974
2,102
2,702
3,880
5,171

3.5
6.1
8.9
9.5
12.2
17.6
23.4

0.020
0.017
0.004
0.010
0.001
0.013
0.024

2,353
3,883

37.7
62.3

8,858
13,222

40.1
59.9

0.041
0.041

3,012
3,224

48.3
51.7

11,513
10,567

52.1
47.9

0.001
0.001

5,202
1,012
22

83.4
16.2
0.4

19,315
2,721
44

87.5
12.3
0.2

0.007
0.006
0.011

6,145
91

98.5
1.5

21,811
269

98.8
1.2

0.018
0.018

150
240
9
413
2,374

2.4
3.9
0.1
6.6
38.1

458
714
30
976
6,409

2.1
3.2
0.1
4.4
29.0

0.009
0.009
0.001
0.025
0.033

Age
4-5

n
246

%
3.8

n
57,793

*Standardized Difference.
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n

%

n

%

d*

Table 3. 2. Propensity score model of receiving an atypical antipsychotic medication
Confounder
Age
4-5
6-11
12-18
Sex
Male
Female
Race
White
Black
Hispanic
Others
Region of residence
Northeast
Midwest
West
South
Annual household income
≤ $29,999
$30,000-39,999
$40,000-49,999
$50,000-59,999
$60,000-74,999
$75,000-99,999
≥ $100,000
Number of outpatient visits
0-5

OR

95% CI

Reference
2.68*
3.26*

2.34-3.01
0.85-3.73

Reference
0.54*

0.51-0.57

Reference
1.25*
0.86*
0.88*

1.10-1.43
0.77-0.95
0.80-0.97

Reference
0.99
1.07*
1.07

0.91-1.10
1.23-1.52
0.98-1.17

Reference
1.01

0.89-1.15

0.80*
0.74*
0.63*
0.58*
0.48*

0.72-0.89
0.66-0.82
0.57-0.69
0.53-0.63
0.44-0.52

Reference

6+
3.84*
3.61-4.08
Number of drugs prescribed (different generic name drugs)
0-3
Reference
4+
2.04*
1.93-2.17
Number of hospitalizations
0
Reference
1-3
4+
Number of ER visits
0

5.94*
3.10*

5.45-6.47
1.78-5.40

Reference

1+
Baseline comorbidities and drug use

0.77*

0.60-0.98

Obesity
Cardiovascular disease

1.03
0.79*

0.85-1.24
0.68-0.93

Pregnancy
Benzodiazepine use

0.31*
1.95*

0.15-0.65
1.71-2.22

Antidepressant use

12.01*

11.28-12.80

*Significant at 5% significance level
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Figure 3. 2. Propensity score distribution
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Figure 3. 3. Kaplan-Meier curve estimating the probability of type II diabetes
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Chapter 4: A decision analysis of atypical antipsychotics treatment in the stimulant
failed ADHD children and adolescents.

A. Background
Attention-deficit/hyperactivity

disorder

(ADHD)

is

the

most

common

neurobehavioral disorder of childhood, characterized by having trouble paying
attention, not being able to control impulsive behaviors, and being overly active.11 Those
with ADHD may experience academic underachievement, troublesome interpersonal
relationship development, and low self-esteem. While medication therapy and/or
behavior therapy are recommended for the ADHD treatment, medication therapy has
been reported as the most cost-effective choice.71 Medication therapy usually initiates
with stimulants such as amphetamine derivatives (e.g., Adderall), which are FDAapproved stimulant medications for ADHD. Although the symptoms are successfully
managed with stimulants in most ADHD patients for the short term (6-10 weeks),19-21 an
alternative medication regimen is often considered due to the adverse side effects,
tolerance development or lack of symptom improvement.24 Some of selective
norepinephrine reuptake inhibitor (atomoxetine) and selective α2-adrenergic agonists
(clonidine, guanfacine) are non-stimulant ADHD medications approved by FDA and
they are recommended as an alternative to stimulants.11
However, a growing number of ADHD children and adolescents are prescribed
with atypical antipsychotics (AAPs),8,22,23 although it is not yet justified with evidence.
Findings about the clinical effectiveness of AAPs in ADHD are mixed with different
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conclusions. Moreover, several adverse side effects were reported as being associated
with AAPs, which include weight gain,34,38,40 type II diabetes,28,46,57 and QTc interval
prolongation.72,73 Therefore, the expected health outcomes based on clinical drug
effectiveness and the risk of adverse effects need to be estimated for AAPs before
considering them as a stimulant alternative. This is also true for other non-stimulant
medications as they have risks of several adverse effects (e.g., high blood pressure74
and/or suicidal ideation75 in atomoxetine users, bradycardia76,77 in clonidine or
guanfacine users). Then, health care providers and patients will be able to compare the
expected health outcomes between strategies and take that into account when they make
decisions about their treatment strategy.
Furthermore, in addition to the expected health outcome, decision-making
depends heavily on health care costs as well. Evaluating the combination of health
outcomes and costs, which is referred to as “cost-effectiveness”, is one of the most
critical elements when choosing the appropriate therapy among multiple strategies.
Therefore, the aims of this paper are: (1) to estimate the expected health
outcomes of AAPs and other non-stimulant ADHD medications based on trade-offs
between clinical effectiveness and adverse effects and (2) to evaluate cost-effectiveness
of AAPs compared to other non-stimulant ADHD medications. Both aims target the
stimulant-failed ADHD children and adolescents.
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B. Material and methods
We conducted a decision analysis estimating trade-offs between individual level
health benefits and risks in treating ADHD children and adolescents who failed the
initial stimulant treatment and require non-stimulant subsequent pharmacotherapy. The
analysis is intended to address whether atypical antipsychotics (AAPs) should be
recommended for ADHD children and adolescents, compared to other alternatives to
stimulants.

The Decision Tree
Most of ADHD patients who choose to receive medication therapy start their
treatment with a stimulant. However, due to a lack of effectiveness or tolerance
development, a subset of the patients cannot be treated with stimulants anymore and
this situation is where we intend our study to be implemented. In other words, the
starting point of the decision tree is where the prescriber and patient seek an alternative
treatment strategy as a replacement of stimulant, among three medication choices: (1)
AAP (aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) (2)
selective norepinephrine reuptake inhibitor (atomoxetine), and (3) alpha-2 adrenergic
agonists (clonidine, guanfacine). (Figure 4. 1) The square box at the start of the decision
tree is a decision node and represents the decision to be made by the prescriber and
patient. The branches coming out of the decision node represent the range of possible
pathways that could result from different choices. Each pathway consists of a series of
branches that leads to particular events that might be experienced by a patient. In this
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study, those events are ADHD symptoms, weight gain, type II diabetes, suicidal
ideation, and cardiovascular events such as QTc interval prolongation, high blood
pressure, or bradycardia. Since it is not certain which events a patient will experience,
such uncertain events are defined by circular nodes (chance nodes). The endpoint of the
decision analysis was 1 year of treatment with 28 different pathways. In this model, the
expected health outcomes are estimated using quality-adjusted life years (QALYs) that
are weighed on a basis of the probabilities of clinical drug effectiveness and side effects.

Estimating Probabilities and Quality-Adjusted Life Years (QALYs)
Probability estimates were derived from literature review. (Table 4. 1) Based on a
systematic search of the literature, we chose a methodologically well-designed study to
obtain a baseline estimate. If multiple studies exist for one estimate, the average was
calculated.78 The Supplementary Appendix provides the conversion process used to
create probabilities that have the minimum value of 0 and the maximum value of 1.
For the baseline probability estimate of AAPs’ effectiveness in ADHD, three
randomized controlled trial (RCT) papers were used.79-81 Although those studies are
restricted to risperidone79,80 and aripiprazole81 only, we assumed that other AAP agents
will have a similar effectiveness since they share the similar mechanism of action.
The adverse side effects associated with AAP including weight gain, type II
diabetes, and QTc interval prolongation were examined. The baseline probability of
weight gain was obtained from three cohort studies in which AAP users were compared
with non-users.34,38,40 For type II diabetes, we based our assumptions on two
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observational studies.46,57 For the AAP-associated cardiovascular events, we obtained the
baseline probability of QTc interval prolongation by averaging the findings of a RCT
conducted by Hough et al.,72 and a case-control study conducted by Correll et al.73
We obtained our assumptions about the drug effectiveness of atomoxetine from
RCTs.82-86 The average estimate was 0.62 with a small variation. For the potential side
effects of atomoxetine, there is a black-box warning on atomoxetine concerning suicidal
ideation. The baseline probability of experiencing suicidal ideation in pediatric patients
was estimated to be 0.0037 from a meta-analysis conducted by Bangs et al.75 As another
adverse side effect of atomoxetine, the baseline probability of having increased diastolic
blood pressure was estimated from a RCT conducted by Wernicke et al.74
The baseline probability of the effectiveness of clonidine or guanfacine (hereafter
referred to as clonidine/guanfacine) was obtained from three RCTs.76,87,88 Similar to
atomoxetine studies, the average estimates was 0.63 with a small variation in
clonidine/guanfacine. One of the major adverse side effects in those medications,
bradycardia, was examined in two RCTs and the average estimate was used as the
baseline probability.76,77
In order to calculate QALYs for each pathway in the decision tree as the health
outcome, we derived QALY weights from a literature review (Table 4. 2). Papers that
were chosen to estimate QALY weights for ADHD, overweight/obese, diabetes, and
cardiovascular events (QTc interval elongation, increased diastolic blood pressure, and
bradycardia) were consistent in using PedsQLTM 4.0 (Pediatric Quality of Life
inventoryTM Version 4.0) as the measurement instrument.89-92 The PedsQL is a scale
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designed to measure quality of life in the pediatric population. However, to our
knowledge, the QALY weights for suicidal ideation in the pediatric population have not
been published, therefore, we chose a study conducted by Goldney et al., in which a
QALY weight was estimated in those age 15 and over using the Assessment of Quality
of Life (AQoL) instrument.93
The papers we used to estimate QALYs in our analyses also reported the average
QALY weights from a healthy population as a control. Theoretically, a perfect health
state has the QALY weight of 1 but the average QALY weights of the healthy population
from papers were less than 1. In order to capture the QALY weight contributed to the
conditions we are interested in, the QALY weights of health outcomes were rescaled to
reflect the relative difference from the perfect health state which has the value of 1. This
process involves taking the difference between the QALY weights of the study
population and the healthy population, and use the difference as the disutility relative to
the perfect health state.
Using QALY weights derived from literature, QALYs over one year of ADHD
treatment were estimated. Health outcomes beyond this time were not estimated due to
the short-term nature of better quality trials. Also, it was assumed that health benefits
and adverse side effects seen within ~6 weeks after initial treatment will persist for a
year as medication treatment continues. More specifically, this is applied to drug
effectiveness, QTc interval prolongation, increased diastolic blood pressure, suicidal
ideation and bradycardia. For the AAP-associated weight gain, since the significant
weight gain was not observed in 6-week trial79 but observed in 12-week trial40, we
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assumed that the notable weight gain would take effect approximately between 6 weeks
and 3 months after initiating AAP treatment and persist throughout the treatment
period. For the AAP-associated type II diabetes, it was assumed to occur within 6
months after initiation of therapy, as reported in several children/adolescent treatment
trials.94,95
We were not able to find studies that measured health-related quality of life
specifically associated with QTc interval prolongation, high blood pressure, and
bradycardia in the pediatric population. Instead, we used a study conducted by Uzrak et
al.(2008) in which quality of life scores were stratified by disease severity. They
categorized disease severity as follows: 1, mild cardiovascular disease (CVD) requiring
no therapy or effectively treated nonoperatively (cathether therapy); 2, moderate CVD
requiring no therapy or surgically corrected (curative); 3, surgically treated CVD (≥1
procedure) with significant residua or need for additional surgery; 4, complex or severe
CVD, uncorrectable or palliated (includes single ventricle). We took the average score of
severity 1 and 2 as the baseline estimate of QTc interval prolongation, high blood
pressure, and bradycardia, since those conditions may not require any medical
procedure in some cases but they are risk factors of other heart diseases.

Calculating the tree
We used the ‘rolling back’ process to calculate the decision tree. This involves
working from the right-hand side of the tree towards left, calculating expected QALYs at
each chance node, until arriving at the index decision.
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Cost Estimation
Expected costs were derived from a retrospective cohort study conducted by
Sikirica et al.24 In their study, ADHD children and adolescents who received nonstimulant therapy were followed for one or more years after the initiation of the
treatment and total health care costs accrued to the patients were estimated in AAP
users and non-AAP users (They grouped atmoxetine users and clonidine/guanfacine
users together as non-AAP users). In order to control for potential selection bias, Sikirica
et al. matched the two groups using patient demographics, geographic region, year of
therapy initiation, stimulant use history, comorbidity, all-cause and mental healthrelated medical care utilization and pharmacy costs during the 6-month pre-index
period. Also, they excluded patients who have any medical claims associated with
conditions that are frequently treated with AAPs (schizophrenia, bipolar disorder, etc.)
to increase the likelihood that patients received AAPs for ADHD and not other
indications. The result indicated that the average annual total health care cost for AAP
users were $6,934, while it was $4,748 for non-AAP users (P<0.001). For non-AAP users,
we assumed that the expected costs of atomoxetine and guanfacine/clonidine would not
be significantly different because they have the close estimates of the average monthly
drug costs ($239 vs. $212, respectively)96, drug effectiveness (0.63 vs. 0.63, respectively),
and health outcomes (0.94 vs. 0.95, respectively).
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Sensitivity Analyses
Multiple sensitivity analyses were conducted to evaluate the robustness of our
conclusion. First, we conducted the one-way deterministic sensitivity analysis for
estimating expected QALYs. In the analysis, the expected QALYs were examined as one
variable varies across the plausible range (Tables 4. 1 and 4. 2), while holding other
variables constant. Second, a Monte Carlo probabilistic sensitivity analysis was
performed to examine the cost-effectiveness of three strategies in 50,000 simulations. The
beta distribution was used for probabilities and QALYs, and the gamma distribution
was used for costs. viii

C. Results
Base Case Analysis
Over one year of ADHD medication treatment, the highest QALY was estimated
for clonidine/guanfacine (expected QALY 0.95), followed by atomoxetine (expected
QALY 0.94). (Table 4. 3, left) Atypical antipsychotics yielded the lowest health outcome
with the expected QALY of 0.84.
In the cost-effectiveness analysis, the strategy of AAPs was “dominated” as it
was less effective and costed more than other two strategies. Compared to
clonidine/guanfacine, AAPs provided a lower QALY (0.11 QALY lost) at an additional

The beta distribution restricts values from 0 to 1 and allows various shapes,
and the gamma distribution restricts values zero or nonnegative and takes a right
skewed form.
viii
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cost of $2,186 on average. Compared to atomoxetine, AAPs resulted in 0.10 QALY lost at
an additional cost of $2,186.

One-Way Sensitivity Analyses for Expected Health Outcomes
One-way deterministic sensitivity analyses indicated that our finding from the
base case analysis about AAPs as the less effective strategy was robust in all variables.
Also, we identified variables with the most influence on incremental QALYs from the
analyses. The result of comparing AAPs to clonidine/guanfacine is shown in a tornado
diagram (Figure 4. 2). The QALYs of having untreated ADHD (i.e., medication is not
effective) had the most impact on the change in health outcomes. The QALYs of having
overweight/obesity were also shown to have a comparably large impact. Among
probabilities, the probability of AAP effectiveness was the most influential variable,
followed by the probability of having AAP associated type II diabetes. The comparison
between AAPs and atomoxetine lead to the same conclusions; in which the QALYs of
having untreated ADHD and having overweight/obesity, followed by the probability of
AAP effectiveness, were the most influential variables.

Probabilistic Sensitivity Analyses for Cost-Effectiveness
The simulated cost-effectiveness derived from the Monte Carlo probabilistic
sensitivity analysis is presented with a scatter plot in Figure 4. 3. The closer a point is to
the right-bottom corner of the chart, the more cost-effective it is. It is observed that the
cost-effectiveness points of clonidine/guanfacine and atomoxetine are relatively more
72

concentrated around the right-bottom corner of the chart than AAPs. The costeffectiveness points of AAPs are spread over a larger area, indicating the higher
frequency of being less cost-effective than other strategies.
The average costs and expected QALYs from the base case analysis were
compared to the ones generated from the probabilistic sensitivity analysis (Table 4. 3,
right). The average cost-effectiveness ratio is smaller in the probabilistic sensitivity
analysis compared to the base case analysis for AAPs (Table 4. 3, left), while it is larger
in the probabilistic sensitivity for other strategies. However, the conclusion about AAPs
being the dominated strategy is consistent in both analyses.

D. Discussion
The aims of the study were to: (1) estimate expected QALYs for non-stimulant
medications in ADHD children and adolescents who have failed stimulants and (2)
examine whether atypical antipsychotics (AAPs) should be recommended for ADHD
children and adolescents as a cost-effective strategy, compared to other alternatives of
stimulants. We developed a decision tree with the probabilities and QALYs of events
followed by a strategy. Our decision analysis showed that AAPs lead to the lower
expected QALYs than other strategies. Also, AAPs were not a favored choice for the
stimulant-failed ADHD pediatric population with respect to cost-effectiveness and
should not be recommended over other strategies, since it is less effective and costs more.
This is depicted on the cost-effectiveness plane, as drawn in Figure 4. 4, where point A
represents the AAP pharmacotherapy. The incremental ratio, compared to other
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strategies (O), is OA. The “northwest” quadrant of the cost-effectiveness plane for which
cost is increasing and quality is decreasing (“dominated”) is where the AAP
pharmacotherapy is located. It is generally uncontroversial to reject such strategies, and
therefore, we did not present an incremental cost-effectiveness ratio (ICER), although it
is typically shown in many cost-effective analyses.
In our decision tree model, the option of “no treatment” was not included
because we assumed that the decision about whether a patient will receive the
pharmacotherapy or not occurs before they initiate a stimulant treatment. Once failed
with stimulant, the patient would seek alternative medications to treat ADHD based on
the prior decision. However, it is possible that the patient and his/her prescriber
consider no treatment when they make a decision after the stimulant failure. If this is the
case, the conclusions of this paper may not be applicable, depending on the costs and
expected health outcomes of not treating ADHD.
The findings of this paper are best implemented in treating ADHD children and
adolescents who do not have comorbid mental disorders for which AAPs are frequently
prescribed, such as schizophrenia, bipolar disorder, or autism spectrum disorders. The
estimated effectiveness of medications in our decision model is from clinical trials
measuring the drug effectiveness on ADHD only. Therefore, the result could be different
when another comorbid mental disorder is present.
Also, we used the QALY of overweight/obesity and the probability of weight
gain when estimating the expected health outcomes in the analyses. However, one
should note that the weight gain may not necessarily result in overweight or obesity.
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Considering our tornado diagram identifying the QALYs of overweight/obesity as the
second most influential variable on the change in health outcome (Figure 4. 3), the
expected health outcomes in AAPs could have been underestimated.
When implementing the conclusions of this paper, our assumption that the
health care costs of atomoxetine treatment were not significantly different from that of
clonidine/guanfacine should be considered as a study limitation. For example, although
our analyses suggested that the most cost-effective choice of stimulant alternative
pharmacotherapy was clonidine/guanfacine over atomoxetine, the conclusion could be
changed depending on the costs associated with each strategy, as the price differs by
manufacturers (brand name drugs vs. generic drugs) and the formulation of the drug
(extended release vs. immediate release). The rank of cost-effectiveness could be easily
affected by the costs, because the expected health outcomes of clonidine/guanfacine and
atomoxetine are similar (expected QALYs 0.95 vs. 0.94, respectively). The primary aim of
the study was to evaluate the cost-effectiveness of AAP compared to other alternatives,
and the decision making between the two non-AAP medications needs further
specification.
Another study limitation was the inclusion of type I diabetes when estimating
QALY weights for AAP associated side effects. We based our assumption about QALY
weights for type II diabetes on the study conducted by Varni et al., in which the quality
of life for the both of type I and type II diabetes pediatric patients were assessed. It is
possible that the quality of life for type I diabetes patients is inherently different from
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type II diabetes patients, and the estimated QALY in this paper may not reflect the true
value of type II diabetes.
Clearly, the side effects associated with each strategy is not limited to the ones in
the decision model. Some side effects associated with taking medications such as
headache, nausea, vomiting, fatigue, dizziness, etc., were omitted because they are likely
to be common in all strategies and the probabilities and impact on quality of life would
be cancelled out during the analyses. However, side effects that are not included in the
model but significantly affect expected health outcomes could draw different
conclusions. For example, we used QTc interval prolongation as an AAP associated side
effect, but the risk of other cardiovascular events including ischemic/pulmonary heart
disease, arrhythmias and cardiomegaly was reported by McIntyre et al. They examined
AAP-related cardiovascular events in children and adolescents at two levels of
comparison: the primary comparison was performed between AAP users and non-users
and secondary comparison was performed between single AAP users and multiple AAP
users. We did not use their result for two reasons: (1) in the primary comparison, the
confounders adjusted in the analysis were limited to age (≤ 12 years or ≥ 13 years), sex
(male or female), and ethnicity (African American or other). The level of confounder
adjustment is too weak to conclude a causal relationship between an AAP and
cardiovascular events since AAP users are likely to be sicker than the untreated control
group and cardiovascular events occurred in AAP users might not have been caused by
an AAP. (2) While it is more appropriate to assume that our study population has not
been treated with AAPs yet, they compared multiple AAP users to single AAP users in
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the secondary comparison. However, it is possible that an AAP causes other
cardiovascular events in addition to QTc interval prolongation and the expected health
outcome could have been underestimated in this paper.
In the policy decision making process, benefit-cost analysis may lead to a
substantially different ranking of alternatives than cost-effectiveness analysis. While
cost-effectiveness analysis look for cost-saving alternatives given an equivalent outcome,
benefit-cost analysis focuses more on options that have the highest magnitude of net
benefits. For instance, it is possible that a therapeutic choice with a higher net health
benefit may not be preferred by cost-effectiveness analysis due to its high costs. Such
difference in decision making perspective ultimately leads our next step to using
willingness to pay measures. Since the money value that people place on health
improvement is usually not observable, health services researchers have been using
contingent valuation in which subjects are asked how much they are willing to pay for a
health change in a hypothetical market setting. By replacing our health outcomes
measured in utility to willingness to pay, a decision can be made based on the
magnitude of net benefit and it may affect our recommendations about AAP use.
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Figure 4. 1. Structure of the decision tree
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Table 4. 1. Probability estimates
Variable
Atypical antipsychotic
Effectiveness
Weight gain
Type II diabetes
QTc interval prolongation
Atomoxetine
Effectiveness
Increased blood pressure
Suicidal ideation
Clonodine/guanfacine
Effectiveness
Bradycardia

Baseline

Variation range
Low
High

0.22
0.7
0.38
0.53

0
0.65
0
0

0.65
0.8
0.84
0.97

0.63
0.56
0.0037

0.6
0
0.0007

0.64
0.88
0.0044

0.63
0.59

0.6
0.17

0.65
0.85
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Table 4. 2. Utility estimates
Variable
Untreated ADHD
Overweight/obese
Diabetes
QTc interval prolongation
High blood pressure
Bradycardia
Suicidal ideation

Baseline

Variation range
Low
High
0.5583
1
0.74485
1
0.92855
1
0.727
1
0.727
1
0.727
1
0.4194
0.8118

0.8673
0.9249
0.9847
0.9913
0.9913
0.9913
0.6156
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Figure 4. 2. Tornado Diagram at AAPs vs. clonidine/guanfacine

QALY of ADHD not treated
QALY of overweight/obesity
Probability of AAPs effectiveness
QALY of cardiovascular events
QALY of Type II diabetes
Probability of Type II diabetes
Probability of overweight/obesity
Probability of QTc interval prolongation
Probability of clonidine/guanfacine
effectiveness
Probability of bradycardia

81

82

Figure 4. 3. Cost-effectiveness scatter plot
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E. Supplementary Appendix
This section provides supplementary material for the primary paper, including a more
detailed presentation of several methodologic points. They should be read in
conjunction with the primary paper.
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Standardizing probabilities from different forms presented in literature
Probabilities of events in our decision tree were obtained in various forms from
the literature. One of the typical ways of presenting the effectiveness/safety of a drug in
a randomized control trial (RCT) is to use a two by two table. Also, many RCTs report
effect size, which is calculated as the difference between the treatment group mean and
the control group mean divided by pooled standard deviation (i.e., effect size =
(treatment mean – control mean)/pooled SD). However, these are rarely used in
observational studies. For example, studies that assessed antipsychotic agent associated
weight gain reported the average change in body weights with standard deviation. In
order to convert the different forms of probabilities into a standardized probability that
takes 0 as the lowest possible value and 1 as the highest possible value, we used
following methods.
a. Calculating the standardized probability from two by two table.97
The effectiveness/safety of a drug can be expressed using two by two table in a
RCT. For example, following table is based on the result of RCT conducted by
Daviss et al. (2008).77
Bradycardia

No Bradycardia

Clonidine-treated (n=31)

7

24

Placebo (n=30)

1

29
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They reported that the probability of having bradycardia in clonidine treated
children was 22.6% (7/31*100 = 22.6%) and the probability of having bradycardia
in placebo group was 3.3% (1/30*100 = 3.3%). The probability of clonidineassociated bradycardia is calculated as the proportionate increase in the
probability of bradycardia resulting from clonidine treatment, which is equal to
0.854 = (0.226-0.033)/0.226.
b. Calculating the standardized probability from effect size.98
The effect size is defined as the difference between the mean outcomes for
treatment and control groups in standard deviation units. Tickle-degnen (2001)
argues that because the effect size is a standard normal deviate, we can assume a
normal distribution to describe the variation of individuals’ responses around
the average outcomes.98 For example, if the effect size is 0.65 as shown in the
guanfacine RCT study conducted by Sallee et al. (2012), the probability of
effectiveness is simply the area under the standard normal curve at 0.65, which is
equal to 0.627.
c.

Calculating the standardized probability from the change in body weight.
The effect size of a drug with respect to weight gain is calculated based on the
reported body weight changes of the treatment and control groups. Once the
effect size is estimated, the standardized probability is obtained using the
standard normal table.98

d. Calculating the standardized probability from hazard ratio. 99
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The hazard ratio is equivalent to the odds that a patient in the treatment group
reaches the endpoint first.99 For example, the probability of developing type II
diabetes first can be derived from the odds of developing type II diabetes first;
which is the probability of developing type II diabetes first divided by the
probability of not developing first:
Hazard ratio (HR) = odds = P/(1 - P);
P = HR/(1 + HR)

Copyright © Minji Sohn 2014
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Chapter 5: Comparative health care cost and utilization in stimulant-treated ADHD
patients

A. Background
In chapter 4, the expected health outcome and cost-effectiveness of AAPs were
assessed in hypothetical ADHD patients who were previously treated with a stimulant
and needed a subsequent pharmacotherapy. One of the study limitations was that I
relied on a single original study article when obtaining the health care cost estimates.
Because the study setting is particularly restricted to post-stimulant therapy, to the best
of our knowledge, a study estimating additional costs accrued to AAP users was not
published until 2013.24 Also, previous studies concerning pediatric AAP use have
focused more on a clinical perspective, such as risks of developing chronic conditions
including obesity31,34,35,38-40 or type II diabetes (T2DM).45,46,57

However, much more

attention needs to be paid to the economic perspective, because a large proportion of
pediatric AAP use is not evidence-based (i.e., ADHD) and potentially causes an overuse
of healthcare resources. Therefore, the purpose of this chapter is to conduct an original
study that compares resource utilization and costs between AAP users and non-AAP
users in stimulant-treated ADHD children and adolescents.
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B. Materials and methods
Data Source and Study Population
Through a new user design approach,61 I assembled a retrospective cohort of 4to 24-year-old members using enrollment files, medical and pharmacy claims data from
the i3 Invision Data Mart (IVDM). These data contain information for a de-identified,
nationally representative sample of 15 million commercially insured and Medicaid
managed care patients. Members between the ages of 4 to 24 at index date (described
below), who had one or more medical claims with a primary diagnosis of ADHD
between January 1, 2007 and December 31, 2009, were considered for this study. The
diagnosis of ADHD was identified using the ICD-9-CM codes of 314.00 (attention-deficit
disorder

without

hyperactivity)

and

314.01

(attention-deficit

disorder

with

hyperactivity). Subjects were also required to have made one or more claims for a
stimulant prescription. The stimulant prescription was identified using NDCs which
corresponded to a generic drug name including dexmethylphenidate, mixed
amphetamine salts, methylphenidate, lisdexamfetamine, or dextroamphetamine.

Exposure
My study compared an AAP user to a non-AAP user. Subjects were considered
to be exposed to an AAP if they had at least one prescription for any of the available
AAPs, which include aripiprazole, olanzapine, paliperidone, quetiapine, risperidone,
and ziprasidone. AAP users were classified as incident or new users (AAP users,
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hereafter) and included in the analysis if they met all of the following eligibility criteria:
(1) initial dispensing date of an AAP (defined as the index date) was preceded by a
minimum of six months of continuous enrollment (i.e., pre-index period) and was
followed by a minimum of six months (or a year) of continuous enrollment in the health
plan (i.e., post-index period); (2) did not have medical claims for conditions that are
commonly treated with AAPs. ix; (3) had a 30 day or less gap between stimulant use and
the index date; (4) had greater than 30 days accumulated stimulant supply during the
pre-index period. As a comparison group, subjects were considered non-AAP users if
they had at least one prescription for any of the non-stimulant ADHD drugs, which
include atomoxetine, clonidine or guanfacine. Using the initial dispending date of these
drugs as the index date for non-AAP users, the same sample selection criteria described
above for the AAP users were applied to the non-AAP users. Additionally, subjects with
both AAPs and non-AAP drugs during the observation period were excluded from
analyses. A flow diagram describing the identification process for the groups included
in the analyses is depicted in Figure 5. 1.
The follow-up time for each subject started on the index date and was extended
for six months (or a year) after the index date. This approach was intended in order to
emulate an intention-to-treat analysis similar to randomized controlled trials.

ix

Those conditions were reported by Sikirica et al. and include schizophrenia (ICD-9-CM, 295),
bipolar disorder (ICD-9-CM, 296.0; 296.1; 296.4-296.8), psychotic disorder with
delusions/hallucinations (ICD-9-CM, 293.81; 293.82), paranoia (ICD-9-CM, 297.1; 297.3), psychosis
(ICD-9-CM, 298.8; 298.9), tics/Tourett’s syndrome (ICD-9-CM, 307.2; 307.23), or dementia (ICD-9CM; 290, 294.1)
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Outcome
The outcome of interest in my study was health care service utilization and costs
during six months (or one year) after the index date. Health care service utilization was
assessed using the number of outpatient visits, inpatient visits, and emergency room
visits. Total health care costs were calculated by adding total prescription costs to total
medical costs. Total prescription costs were further categorized into index drug costs
and non-index drug costs. Total medical costs were further categorized into mental
health service related costs and non-mental health service related costs. For each
category, costs associated with outpatient visits, inpatient visits, and emergency room
visits were estimated. A mental health service refers to a medical visit with a primary
diagnosis of a mental health disorder (ICD-9-CM 290.XX-319.XX). I used costs that
occurred to third-party payers, which excludes deductibles, coinsurance, copayments
and other out-of-pocket costs paid by patients. All costs were converted to 2012 US
dollars based on the medical component of consumer price index. x

Covariates
To control for potential selection bias and confounding, I used the inverse
probability of treatment weighting (IPTW) method in which each subject is weighted
based on their inverse propensity to receive an AAP. The propensity for each subject
was estimated through logistic regression as the probability of starting AAP treatment
x

Source: U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Available
at: http://www.bls.gov.cpi/. Accessed April 7, 2014)
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during my study period, based on their baseline characteristics. Specifically, the
following covariates were included: age, sex, race, geographic region, household income,
primary health care payer source, the duration of stimulant use, the number of different
stimulants used, the presence of hyperactivity in attention deficit disorder, the health
care utilization intensity and physical/mental comorbidity during the pre-index period.
Health care utilization was measured by four variables: the number of hospitalizations,
the number of emergency room (ER) visits, the number of outpatient services, and the
number of filled prescriptions with different generic names (excluding sitmulants). For
comorbidity, we looked for conditions that are not only associated with AAP use, but
also likely to affect health care costs/utilization. Those conditions include physical
conditions such as obesity, diabetes, cardiovascular disease , and epilepsy, and mental
conditions such as neurotic disorder, mood disorder, disturbance, developmental
disorder, and adjustment disorder.

Analysis
Baseline characteristics of AAP users and non-AAP users were compared and
tested. All characteristics were included in the analysis as categorical variables and
therefore, chi-square tests were used for all characteristics to assess statistical
significances between the two cohorts. The additional health care costs accrued to AAP
users compared to non-AAP users were estimated using the inverse probability of
treatment weighting. The associated robust standard errors were derived from Taylor-
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linearized variances. Event rate ratios and 95% confidence intervals for health care
service utilization were estimated using the Poisson regression model.

C. Results

Baseline characteristics
A total of 3,437 (2,189 for 12 month post-index observation cohort) patients met
my inclusion criteria. Among those, 1,039 (639) individuals were new AAP users.
Baseline characteristics of cohorts for the six month post-index observation period are
summarized in Table 5. 1. At baseline, differences in patient demographics and
socioeconomic characteristics between the two cohorts were not statistically different,
except that AAP users were more likely to be older than non-AAP users (more
adolescents and young adults). Instead, they were very different in terms of medical
profiles and health care service utilization during the pre-index period. On average,
AAP users used stimulants for a longer duration. Also, they were more likely to have
hyperactivity in addition to the attention deficit disorder. While the presence of physical
comorbidity was not statistically different between two cohorts, AAP users had a much
higher rate of mental comorbidity. Also, the AAP users showed a higher level of health
care utilization during the six month pre-index period, with respect to the number of
outpatient service visits, hospitalizations, and filled prescriptions.

Calculation of propensity scores
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The logistic regression model to evaluate AAP utilization is described in Table 5.
2. The results indicate that older patients were more likely to receive an AAP. Female
patients were less likely to receive an AAP compared to male patients. Annual
household income was significantly associated with AAP use: the propensity to receive
an AAP decreased as the level of household income increased. Compared to private
insurance policy holders, Medicaid enrollees were less likely to use an AAP. While the
longer duration of stimulant use increased the likelihood of using an AAP, the number
of different stimulants used and the presence of hyperactivity did not show a significant
impact on the AAP use. The higher level of health care utilization measured in the
number of outpatient service visits and prescription medications significantly increased
the propensity to receive an AAP. Also, having comorbid mental disorders including
neurotic disorder, mood disorder and disturbance significantly increased the likelihood
of AAP use. The c-statistic was 0.716, indicating a good predictive accuracy of the
logistic regression model.

Health Care Service Utilization
During the six month post-index observation period, over 96 percent of subjects
utilized outpatient health care services one or more times. The average number of
outpatient visits was ten per AAP user and seven per non-AAP user. From the Poisson
regression analysis using IPTW, AAP users had a statistically significant increase in the
likelihood of utilizing outpatient services than non-AAP users (event rate ratio, ERR 1.14;
95% CI 1.04-1.26) (Table 5. 3). For inpatient service utilization, approximately five
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percent of AAP users (N=53) and two percent of non-AAP users (N=40) were
hospitalized at least once. The average number of outpatient visits was 0.08 per AAP
user and 0.02 per non-AAP user. In the IPTW estimation, AAP users showed a
statistically significant increase in the likelihood of being hospitalized than non-AAP
users. (ERR 1.77; 95% CI 1.05-2.98). Nearly everyone in each cohort (≈99%) did not visit
an emergency room (ER) during the six month observation period. The average number
of ER visits was 0.01 per AAP user and 0.02 per non-AAP user. In the Poisson regression
model with IPTW, ER visit rates between two cohorts were not significantly different.
During the 12 month post-index observation period, the relative rate of
outpatient visits between AAP users and non-AAP users were similar to the result for
the six month observation period (ERR 1.18; 95% CI 1.04-1.33). However, the rates of
inpatient and ER visits were not significantly different between two cohorts.

Additional Health Care Costs Accrued to AAP users
The average costs that are additionally accrued to AAP users compared to nonAAP users were estimated using the inverse probability of treatment weighting and
results are shown in Table 5. 4. During the six month observation period after index date,
AAP users had higher health care costs especially associated with prescription
medications and mental health related services. The prescription costs for AAP users
were $900 higher than non-AAP users, mostly owing to the cost of their index drug. The
mental health related service costs for AAP users were $509 higher than non-AAP users.
Non-mental health related costs were not significantly different between two cohorts in
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all categories of services. During the 12 month post-index observation period, the
prescription costs remained higher for AAP users with additional $1,672 vs. non-AAP
users. However, except mental health related outpatient visit costs, both mental health
and non-mental health related medical costs were not significantly different between the
two cohorts.

D. Discussion
The purpose of the study was to compare health care resource utilization and
costs between AAP users and non-AAP users in stimulant-treated ADHD patients. We
found that AAP users were likely to visit a healthcare facility for outpatient and
inpatient services more frequently than non-AAP users. Also, total health care costs
were significantly higher for AAP users with additional costs of $1,393 during six
months and $2,784 during a year after initiating the AAP treatment.
These findings are similar to the previous study conducted by Sikirica et al.
Sikirica et al. used health administrative data collected from commercially insured
members who were between ages sex and twelve. They reported that AAP users had a
higher level of health care utilization and costs than non-AAP users during 12 months
after index date. Interestingly, the additional total health care costs accrued to AAP
users reported in their study are close to my result ($2,341, P<0.001 from Sikirica et al. vs.
$2,784, P=0.007 from my study, both in 2012 dollars). However, it is different from my
study in that their estimates were significantly higher for AAP users in all categories,
while I observed the difference only in prescription costs and mental health related
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outpatient service costs. There are a number of factors that could affect this difference,
which include: (1) different sample size (larger for Sikirica et al.), (2) different age groups
(more restricted for Sikirica et al.), and/or (3) different reimbursement policies
implemented in different health insurance plans.
The additional total health care costs accrued to AAP users were mostly
attributed to prescription medication costs, especially for the index drug. The additional
expenses associated with the index drug for AAP users were $717 during the six month
post-index period, and $1,249 during a year post-index period. This is probably due to
the difference in drug price per unit. The average cost of risperidone, quetiapine and
aripiprazole (the three most frequently used AAPs among pediatric patients) are
estimated to be higher at $491 per month,100 as compared to $239 per month for
atomoxetine and $212 per month for clonidine/guanfacine.96 In addition, during 20072009,

none

of

the AAP

agents

were

available

as

a

generic drug while

clonidine/guanfacine immediate release forms were available as generic drugs at the
lower cost.
In the process of expanding the post-index observation period from six months
to a year, we lost about a third of subjects (N=1,248). Many private health care
enrollment decisions are made on a yearly basis, and requiring continuous enrollment
during six month pre-index and one year post-index period would have excluded those
who have changed their healthcare plan after a year of enrollment between January 1,
2007 and December 31, 2009. Compared to those who were qualified for the one year
post-index observation period (continuously enrolled for at least 12 months but less than
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18 months, N=2,189), those who were qualified only for the six month post-index
observation period (continuously enrolled for at least 12 months but less than 18 months,
N=1,248) were more likely to be older (young adults, OR 1.85; 95% CI 1.42-2.42) and
covered by Medicaid (OR 1.35; 95% CI 1.05-1.73). Also, they had a longer duration of
baseline stimulant use (four to six months, OR 1.24; 95% CI 1.05-1.47), more stimulants
(three or more different generic names, OR 1.39; 95% CI 1.04-1.87) and other prescription
medications (four or more different generic names, OR 1.31 95% CI 1.04-1.66), and more
comorbid mood disorders (OR 1.27; 95% CI 1.06-1.52). Considering that these
characteristics are associated with not only the AAP use, but also the increase in health
care service utilization, our estimates from the 12-month post-index observation period
might have underestimated the true difference in health care costs and utilization
between AAP users and non-AAP users. Another limitation of the study is a relatively
short follow-up. Although the purpose was to assess the health care utilization and costs
during six months or a year after initiating the index drug, the long-term effects of AAPs
are potentially greater when considering the risk of chronic illness associated with AAPs,
which may take a longer time to develop after drug initiation.
Despite such limitations, our study provides strong evidence to the debate
related to pediatric AAP use. There are a number of concerns regarding AAP
unapproved effectiveness and risks of developing chronic conditions including obesity,
cardiovascular disease, and type II diabetes. Whereas much more evidence is focused on
clinical benefits and risks of AAP use, empirical findings about the economic costs are
under-provided. With ADHD as one of the leading conditions for a pediatric patient to
99

receive an AAP, I believe that the findings of the study will have important implications
for the decision-making related to pediatric AAP use.

100

Figure 5. 1. Sample selection flowchart*
ADHD patients (4 ≤ Age ≤ 24) who were continuously enrolled for 12 (or 18) months
N=216,306 (N=162,243)
Excluded:
1. Having conditions that are commonly treated with AAPs;
N=21,557 (N=15,491)
2. Not having a stimulant prescription; N=36,060 (N=26,655)
3. Not having an index drug prescription; N=131,912 (N=98,875)
4. Not having 6 month pre-index and 6 (or 12) month post-index
period; N=14,993 (N=13,496)
5. Having >30 days between stimulant use and initial index drug
use; N=7,139 (N=4,771)
6. Having <30 days of stimulant supply during pre-index period;;
N=75 (N=53)
7. Having both AAP and non-AAP during post-index period; N=242
(N=163)
8. Patient demographic/socioeconomic characteristics not available;
N=891 (N=550)

Eligible study subjects
N=3,437 (N=2,189)
AAP users before matching

Non-users before matching

N=1,039 (N=639)

N=2,398 (N=1,550)

*The number of subjects for 12 months post-index observation period is in parentheses.
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Table 5. 1. Baseline characteristics – 6 month observation cohort
AAP users
(N=1,039)
Baseline Characteristics

N

Non-AAP users
(N=2,398)

%

N

%

Age
Children (age 4-11)
503
48.41
1,463
61.01
Adolescents (age 12-18)
447
43.02
793
33.07
Young adults (age 18-24)
89
8.57
142
5.92
Sex
Male
769
74.01
1,724
71.89
Female
270
25.99
674
28.11
Race
White
858
82.58
2,015
84.03
Black
41
3.95
76
3.17
Other
140
13.47
307
12.80
Region of residence
Northeast
103
9.91
190
7.92
Midwest
322
30.99
794
33.11
South
514
49.47
1,181
49.25
West
100
9.62
233
9.72
Annual household income
≤ $49,999
260
25.02
551
22.98
$50,000-74,999
281
27.05
643
26.81
$75,000-99,999
217
20.89
556
23.19
≥ $100,000
281
27.05
648
27.02
Payer source
Private
996
95.86
2,263
94.37
Medicaid
43
4.14
135
5.63
Baseline stimulant use (duration)
≤ 2 months
183
17.61
576
24.02
2-4 months
378
36.38
876
36.53
4-6 months
478
46.01
946
39.45
Baseline stimulant use (number of different stimulant used)
1
720
69.30
1,705
71.10
2
266
25.60
577
24.06
3+
53
5.10
116
4.84
Attention deficit disorder with hyperactivity (ICD-9-CM, 314.01)
Yes
878
84.50
1,942
80.98
No
161
15.50
456
19.02
Number of non-stimulant drugs prescribed (different generic names)
0-1
206
19.83
837
34.90
2-3
415
39.94
986
41.12
4+
418
40.23
575
23.98
Number of outpatient service visits
0-2
74
7.12
399
16.64
3-5
298
28.68
886
36.95
6-9
279
26.85
578
24.10
10+
388
37.34
535
22.31
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p Value
<0.001
<0.001
0.004
0.201
0.201
0.292
0.249
0.591
0.055
0.223
0.905
0.933
0.194
0.888
0.138
0.989
0.070
0.070
<0.001
0.933
<0.001
0.287
0.335
0.743
0.014
0.014
<0.001
0.520
<0.001
<0.001
<0.001
0.087
<0.001

Table 5. 1. Baseline characteristics –cont’d
AAP users
(N=1,039)
Baseline Characteristics

N

Number of inpatient service visits
0
974
1
51
2+
5
Number of emergency room visits
0
12
1+
1,027
Baseline physical comorbidity*
Obesity
17
Diabetes
6
Cardiovascular disease
4
Epilepsy
11
Baseline mental comorbidity*
Neurotic disorder
245
Mood disorder
286
Disturbance
249
Developmental disorder
58
Adjustment disorder
135

Non-AAP users
(N=2,398)
p Value

%

N

%

93.74
4.91
0.21

2,350
43
14

98.00
1.79
1.35

<0.001
<0.001
<0.001

1.15
98.85

40
2,358

1.67
98.33

0.258
0.258

1.64
0.58
0.38
1.06

32
7
9
19

1.33
0.29
0.38
0.79

0.493
0.210
0.966
0.441

23.58
27.53
23.97
5.58
12.99

315
217
324
147
244

13.14
9.05
13.51
6.13
10.18

<0.001
<0.001
<0.001
0.533
0.015

*These variables are not mutually exclusive.
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Table 5. 2. Propensity score model of receiving an atypical antipsychotic medication
Confounder
Age
Children (age 4-11)
Adolescents (age 12-18)
Young adults (age 19-24)
Sex
Male
Female
Race
White
Black
Others
Region of residence
Northeast
Midwest
West
South
Annual household income

Odds ratio

95% Confidence interval

Reference
1.47*
1.59*

1.24-1.75
1.16-2.19

Reference
0.76*

0.63-0.91

Reference
1.65*
1.09

1.10-2.51
0.86-1.38

Reference
0.70*
0.82
0.76

0.52-0.94
0.57-1.18
0.57-1.01

≤ $49,999
$50,000-74,999

Reference
0.83

0.66-1.04

$75,000-99,999
≥ $100,000

0.66*
0.71*

0.52-0.84
0.56-0.89

Payer source
Private
Reference
Medicaid
0.59*
Baseline stimulant use (duration)
≤ 2 months
Reference
2-4 months
1.39*
4-6 months
1.98*
Baseline stimulant use (number of different stimulant used)
1
Reference
2
1.01
3+
0.95
Attention deficit disorder with hyperactivity (ICD-9-CM, 314.01)
No
Yes

Reference
1.16

0.39-0.89

1.14-1.71
1.59-2.48

0.84-1.22
0.66-1.37

0.94-1.44

Number of non-stimulant drugs prescribed (different generic names)
0-1
Reference
2-3
4+
Number of outpatient service visits
0-2

1.39*
1.98*

1.14-1.71
1.59-2.48

Reference

3-5
6-9

1.49*
1.80*

1.12-2.00
1.32-2.45

10+

2.27*

1.64-3.13
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Table 5. 2. Propensity score model of receiving an atypical antipsychotic medicationcont’d
Confounder
Number of inpatient service visits
0
1
2+
Number of emergency room visits
0
1+
Baseline physical comorbidity
Obesity
Diabetes
Cardiovascular disease
Epilepsy
Baseline mental comorbidity
Neurotic disorder
Mood disorder
Disturbance
Developmental disorder
Adjustment disorder

Odds ratio

95% Confidence interval

Reference
1.17
2.55

0.74-1.87
0.74-8.80

Reference
0.45

0.20-1.00

0.83
1.19
0.75
1.03

0.45-1.51
0.30-4.77
0.21-2.66
0.44-2.42

1.39*
2.54*
1.79*
0.81
0.94

1.12-1.72
2.03-3.17
1.45-2.21
0.57-1.14
0.73-1.21

*Significant at 5% significance level.
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Table 5. 3. Inverse probability of treatment weighted estimation of health care utilization
of AAP users compared to non-AAP users
During 6 month observation
period after index date (N=3,437)

During 12 month observation
period after index date (N=1,908)

Health care utilization

Event rate ratio
(95% confidence
interval)

p
Value

Event rate ratio
(95% confidence
interval)

p
Value

Outpatient service visits

1.14 (1.04-1.26)

0.008

1.18 (1.04-1.33)

0.009

Inpatient service visits
Emergency room visits

1.77 (1.05-2.98)
0.62 (0.23-1.65)

0.033
0.342

1.48 (0.92-2.40)
0.99 (0.33-3.02)

0.108
0.988
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Table 5. 4. Inverse probability of treatment weighted estimation of incremental costs
accrued to AAP users compared to non-AAP users
During 6 month observation period
after index date (N=2,895)

Health care costs
Total prescription costs
Index drug costs
Non-index drug costs
Total medical costs
Mental health related costs
- Outpatient visits
- Inpatient visits
- Emergency room visits
Non-mental health related costs
- Outpatient visits
- Inpatient visits
- Emergency room visits
Total health care costs*

Incremental cost
(± robust standard
error)

p Value

$ 900 (± 63)
$ 717 (± 35)
$ 184 (± 48)
$ 493 (± 350)
$ 509 (± 170)
$ 196 (± 78)
$ 314 (± 139)
-$ 0.2 (± 0.3)
-$ 16 (± 282)
$ 124 (± 226)
-$ 135 (± 122)
-$ 5 (± 4)
$ 1,393 (± 362)

<0.001
<0.001
<0.001
0.159
0.003
0.012
0.024
0.485
0.954
0.583
0.265
0.222
<0.001

*Total prescription costs + total medical costs

Copyright © Minji Sohn 2014
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During 12 month observation
period after index date
(N=1,908)
Incremental cost
(± robust standard
error)
$ 1,672 (± 155)
$ 1,249 (± 87)
$ 423 (± 115)
$ 1,113 (± 1,008)
$ 573 (± 232)
$ 293 (± 157)
$ 281 (± 147)
-$ 1 (± 1)
$ 539 (± 973)
$ 797 (± 868)
-$ 258 (± 275)
$ 0.3 (± 11)
$ 2,784 (± 1,031)

p
Value
<0.001
<0.001
<0.001
0.270
0.014
0.062
0.057
0.092
0.580
0.359
0.348
0.979
0.007

Chapter 6: Conclusion and Policy Recommendations

The extensive use of AAPs by pediatrics is an important policy problem that
imposes serious concerns on public health and economy in the US. As discussed in
chapter 2, a large proportion of total pediatric AAP use is off-label in which the safety
and effectiveness are not yet established. Moreover, among the off-label conditions for
which AAPs were used, ADHD was the most common primary mental diagnosis.
Motivated by this phenomenon, this dissertation further addressed underlying problems
about AAP utilization, and its implication to ADHD children and adolescents.
From public health perspective, the risk of type II diabetes in pediatric AAP
users was estimated in chapter 3. A retrospective cohort study was conducted using
nationally representative data, and the twice higher risk of developing type II diabetes
was estimated for AAP users compared to non-users in pediatrics. Considering that
T2DM is a chronic condition that may persist the rest of a person’s life, its risk that is
imposed on children and adolescents could outweigh the benefit of AAP therapy in
some patients.
From economic efficiency perspective, chapter 4 estimated the cost-effectiveness
of AAPs compared to other ADHD medications in pediatric ADHD patients who have
failed a stimulant therapy. Among non-stimulant ADHD medication treatment
strategies, AAPs resulted in the lower expected health outcome than other ADHD
medications including atomoxetine, clonidine, or guanfacine. Also, AAPs were not a
favored choice with respect to cost-effectiveness, and should not be recommended over
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other strategies. While analyses in chapter 4 were based on estimates derived from
literature review, the chapter 5 reports an original study that compares resource
utilization and costs between atypical antipsychotic (AAP) users and non-AAP users in
ADHD. I found that AAP users were likely to visit a healthcare facility for outpatient
and inpatient services more frequently than non-AAP users. Also, total health care costs
were significantly higher for AAP users with additional costs of $1,393 (2012 dollars)
during six months and $2,784 (2012 dollars) during a year after initiating the AAP
treatment.
With the defined problem and evidences reported in this dissertation, I propose
solutions and policy recommendations that can be implemented at the national/state
government level, the health care provider level and the patient/caregiver level.
First, at the national/state government level, it is important for healthcare service
agencies to recognize that the pediatric AAP use is a potentially inappropriate
utilization. Especially, as primary public organizations involved in regulating mental
health service provision, Substance Abuse Mental Health Services Administration
(SAMHSA), Centers for Medicare and Medicaid Services (CMS), and National
Association of State Mental Health Program Directors (NASMHPD) should work
together so that their funding and billing systems reflect the promotion of standardized
mental health care. Also, current health care surveillance activities could be amended in
a way that the pediatric AAP practice and its impacts are better captured and assessed
by health services researchers. For example, Healthcare Effectiveness Data and
Information Set (HEDIS) is a widely used set of healthcare quality measures in the US.
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While it incorporates a number of measures that assess mentally ill patients’ access to
healthcare services and medication managements, it does not include a measure for
assessing the potential overuse or misuse of antipsychotics. It is recommended that
standard definitions for identifying inappropriate antipsychotic use are developed and
included in the HEDIS and other healthcare quality surveillance tools.
Second, at the healthcare provider level, provider agencies and clinicians should
ensure the provision of quality and evidence based care. One of the reasons why AAPs
were largely used by pediatrics is because they were marketed as a safer choice
compared to typical antipsychotics. However, when making decisions about the AAP
therapy, it should be thoroughly considered that the risk of using an AAP may outweigh
benefits in many children and adolescents.
Third, at the patient/caregiver level, they are encouraged to pursue patient
centered care that is long-term wellness focused. Patient-centered care is defined as
“care that is respectful and responsive to individual patient preferences needs, and
values and ensuring that patient values guide all clinical decisions”. It would be better
implemented if patients/caregivers share information so that the mental health
community becomes more aware of the clinical/economic impacts of pediatric AAP use.

Copyright © Minji Sohn 2014
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